Updated on 2023/07/25

写真a

 
MOTOMURA Kazuya
 
Organization
Graduate School of Medicine Program in Integrated Medicine Clinical Neurosciences Associate professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Associate professor
Contact information
メールアドレス

Degree 1

  1. Doctor (Medical Science) ( 2012.3   Nagoya University ) 

Research Interests 13

  1. 脳機能研究

  2. 脳腫瘍の遺伝子解析

  3. 電気生理学モニタリング

  4. 術中MRI

  5. 覚醒下手術

  6. 脳腫瘍

  7. 脳機能研究

  8. 電気生理学モニタリング

  9. 覚醒下手術

  10. 術中MRI

  11. 脳腫瘍の遺伝子解析

  12. 脳腫瘍

  13. 脳腫瘍(成人脳腫瘍、小児脳腫瘍)

Research Areas 1

  1. Life Science / Neurosurgery

Current Research Project and SDGs 3

  1. 感情の神経基盤の解析:島回に対する浸潤脳腫瘍の及ぼす病態の解明

  2. Establishment of a novel preoperative brain mapping system by navigated navigated transcranial magnetic stimulation (nTMS)

  3. 覚醒下脳機能マッピングによる島皮質または眼窩前頭皮質における自律神経機能研究

Research History 10

  1. Nagoya University Graduate School of Medicine   Department of Neurosurgery   Associate professor

    2016.8

      More details

    Country:Japan

  2. 名古屋大学医学部大学院医学系研究科 脳神経外科学 特任准教授

    2014.4 - 2016.7

      More details

    Country:Japan

  3. 名古屋大学医学部附属病院 脳神経外科 助教

    2013.8 - 2014.3

      More details

    Country:Japan

  4. 名古屋大学医学部大学院医学系研究科 脳神経外科学 特任助教

    2012.12 - 2013.7

      More details

    Country:Japan

  5. フランス・モンペリエ大学 Gui de Chauliac 病院 脳神経外科 客員研究員

    2012.10 - 2012.11

      More details

    Country:France

  6. 世界保健機関(World Health Organization;WHO), 国際がん研究機関(International Agency for Research on Cancer;IARC) 博士研究員

    2011.10 - 2012.9

      More details

    Country:France

  7. 名古屋大学医学部大学院医学系研究科 脳神経外科学 特任助教

    2011.4 - 2011.9

      More details

    Country:Japan

  8. 名古屋大学医学部大学院医学系研究科 脳神経外科学 医員

    2007.10 - 2011.3

      More details

    Country:Japan

  9. 市立四日市病院 脳神経外科 医員

    2004.4 - 2007.9

      More details

    Country:Japan

  10. 社会保険中京病院 研修医

    2002.5 - 2004.3

      More details

    Country:Japan

▼display all

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences   Neurosurgery

    2008.4 - 2011.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1996.4 - 2002.3

      More details

    Country: Japan

Professional Memberships 10

  1. Japan society of neurosurgery

  2. 日本脳神経外科コングレス学会

  3. Japan society of brain tumor

  4. 日本脳腫瘍の外科学会

  5. Japan society of brain tumor pathology

  6. 日本Awake Surgery学会

  7. 日本癌学会

  8. 日本神経心理学会

    2013.9

  9. 日本脳卒中学会

  10. 日本脳神経CI学会

▼display all

Committee Memberships 9

  1. JCOG脳腫瘍グループ   代表委員  

    2022.6   

      More details

    Committee type:Academic society

  2. JCOG脳腫瘍グループ 医療経済評価小委員会   委員  

    2022.3   

      More details

    Committee type:Academic society

  3. 日本脳腫瘍病理学会   評議員  

    2021.6   

  4. Neuro-Oncology Central 運営委員   運営委員  

    2021.3   

  5. 日本脳腫瘍の外科学会   評議員  

    2019.9   

  6. 日本AwakeSurgery学会 運営委員   運営委員  

    2018.9   

  7. 日本脳腫瘍病理学会 事務局幹事   事務局幹事  

    2017   

  8. 東海脳腫瘍手術手技研究会 運営委員   運営委員  

    2017   

  9. 日本脳神経外科学会 評議員   評議員  

    2015   

      More details

    Committee type:Academic society

▼display all

Awards 3

  1. 第25回日本脳腫瘍の外科学会 会長賞

    2020.9  

  2. 一般社団法人日本脳神経外科学会 第78回学術総会 優秀演題賞

    2019.10  

  3. 平成22年度組織的な若手研究者等海外派遣プログラム(第1回)助成金

    2010.7  

 

Papers 95

  1. Latest classification of ependymoma in the molecular era and advances in its treatment: a review.

    Yamaguchi J, Ohka F, Motomura K, Saito R

    Japanese journal of clinical oncology     2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hyad056

    PubMed

  2. [Intraoperative Functional Monitoring in Brain Tumor Surgery].

    Motomura K, Saito R

    No shinkei geka. Neurological surgery   Vol. 51 ( 3 ) page: 481 - 489   2023.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11477/mf.1436204772

    PubMed

  3. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas.

    Nishikawa T, Ohka F, Aoki K, Suzuki H, Motomura K, Yamaguchi J, Maeda S, Kibe Y, Shimizu H, Natsume A, Innan H, Saito R

    Brain tumor pathology     2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Brain Tumor Pathology  

    Adult-type diffuse gliomas are divided into Astrocytoma, IDH-mutant, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioblastoma, IDH-wildtype based on the IDH mutation, and 1p/19q codeletion status. To determine the treatment strategy for these tumors, pre-operative prediction of IDH mutation and 1p/19q codeletion status might be effective. Computer-aided diagnosis (CADx) systems using machine learning have been noted as innovative diagnostic methods. However, it is difficult to promote the clinical application of machine learning systems at each institute because the support of various specialists is essential. In this study, we established an easy-to-use computer-aided diagnosis system using Microsoft Azure Machine Learning Studio (MAMLS) to predict these statuses. We constructed an analysis model using 258 adult-type diffuse glioma cases from The Cancer Genome Atlas (TCGA) cohort. Using MRI T2-weighted images, the overall accuracy, sensitivity, and specificity for the prediction of IDH mutation and 1p/19q codeletion were 86.9%, 80.9%, and 92.0%, and 94.7%, 94.1%, and 95.1%, respectively. We also constructed an reliable analysis model for the prediction of IDH mutation and 1p/19q codeletion using an independent Nagoya cohort including 202 cases. These analysis models were established within 30 min. This easy-to-use CADx system might be useful for the clinical application of CADx in various institutes.

    DOI: 10.1007/s10014-023-00459-4

    Web of Science

    Scopus

    PubMed

  4. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.

    Motomura K, Kibe Y, Ohka F, Aoki K, Yamaguchi J, Saito R

    Brain tumor pathology     2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Brain Tumor Pathology  

    The 2021 World Health Organization (WHO) classification of central nervous system tumors applied molecular criteria and further integrated histological and molecular diagnosis of gliomas. This classification allows for the diagnosis of isocitrate dehydrogenase wild-type (IDHwt) glioblastoma (GBM), and WHO grade 4 with histologically lower-grade gliomas (LrGGs), even in the absence of high-grade histopathologic features, such as necrosis and/or microvascular proliferation. They contain at least one of the following molecular features: epidermal growth factor receptor amplification, chromosome 7 gain/10 loss, or telomerase reverse transcriptase promoter mutation. In the imaging features at the time of histological diagnosis, a gliomatosis cerebri growth pattern was frequently observed in these tumors. Furthermore, this growth pattern was significantly higher in IDHwt GBM, WHO grade 4, with histological grade II gliomas. Although the exact prognosis of IDHwt GBM, WHO grade 4, with histologically LGGs remains unknown, its OS was approximately 1–2 years similar to that of histologically IDHwt GBM, WHO grade 4, despite histopathological features similar to IDHmut LrGGs. These findings reinforce the need for the analysis of molecular features, regardless of presenting similar clinical characteristics and imaging features to IDHmut LrGGs.

    DOI: 10.1007/s10014-023-00458-5

    Web of Science

    Scopus

    PubMed

  5. Efficacy and safety of bevacizumab, irinotecan, and temozolomide combination for relapsed or refractory pediatric central nervous system embryonal tumor: a single-institution study.

    Shiba Y, Motomura K, Taniguchi R, Kurimoto M, Mizutani K, Ohka F, Aoki K, Ito E, Nishikawa T, Yamaguchi J, Kibe Y, Shimizu H, Maeda S, Nakashima T, Suzuki H, Muramatsu H, Takahashi Y, Saito R

    Journal of neurosurgery. Pediatrics     page: 1 - 9   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/2023.1.PEDS22345

    PubMed

  6. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.

    Yamaguchi J, Ohka F, Kitano Y, Maeda S, Motomura K, Aoki K, Takeuchi K, Nagata Y, Hattori H, Tsujiuchi T, Motomura A, Nishikawa T, Kibe Y, Shinjo K, Kondo Y, Saito R

    Cancer science     2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15762

    PubMed

  7. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series. Reviewed

    Kibe Y, Motomura K, Ohka F, Aoki K, Shimizu H, Yamaguchi J, Nishikawa T, Saito R

    Scientific reports   Vol. 13 ( 1 ) page: 23   2023.1

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    Isocitrate dehydrogenase wild-type (IDHwt) diffuse astrocytomas feature highly infiltrative patterns, such as a gliomatosis cerebri growth pattern with widespread involvement. Among these tumors, localized IDHwt histologically diffuse astrocytomas are rarer than the infiltrative type. The aim of this study was to assess and describe the clinical, radiographic, histopathological, and molecular characteristics of this rare type of IDHwt histologically diffuse astrocytomas and thereby provide more information on how its features affect clinical prognoses and outcomes. We retrospectively analyzed the records of five patients with localized IDHwt histologically diffuse astrocytomas between July 2017 and January 2020. All patients were female, and their mean age at the time of the initial treatment was 55.0 years. All patients had focal disease that did not include gliomatosis cerebri or multifocal disease. All patients received a histopathological diagnosis of diffuse astrocytomas at the time of the initial treatment. For recurrent tumors, second surgeries were performed at a mean of 12.4 months after the initial surgery. A histopathological diagnosis of glioblastoma was made in four patients and one of gliosarcoma in one patient. The initial status of IDH1, IDH2, H3F3A, HIST1H3B, and BRAF was “wild-type” in all patients. TERT promoter mutations (C250T or C228T) were detected in four patients. No tumors harbored a 1p/19q codeletion, EGFR amplification, or chromosome 7 gain/10 loss (+ 7/ − 10). We assessed clinical cases of localized IDHwt histologically diffuse astrocytomas that resulted in malignant recurrence and a poor clinical prognosis similar to that of glioblastomas. Our case series suggests that even in patients with histologically diffuse astrocytomas and those who present with radiographic imaging findings suggestive of a localized tumor mass, physicians should consider the possibility of IDHwt histologically diffuse astrocytomas.

    DOI: 10.1038/s41598-022-25928-2

    Scopus

    PubMed

  8. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.

    Yamaguchi J, Ohka F, Lushun C, Motomura K, Aoki K, Takeuchi K, Nagata Y, Ito S, Mizutani N, Ohno M, Suzaki N, Takasu S, Seki Y, Kano T, Wakabayashi K, Oyama H, Kurahashi S, Tanahashi K, Hirano M, Shimizu H, Kitano Y, Maeda S, Yamazaki S, Wakabayashi T, Kondo Y, Natsume A, Saito R

    Cancer medicine     2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cam4.5512

    PubMed

  9. [A case of bilingual aphasia with language mixing between Japanese and English caused by superior longitudinal fasciculus lesion-a study using functional MRI and diffusion tensor imaging].

    Sawaki M, Yamamoto H, Motomura K, Yamamoto M, Furukawa K, Saito O

    Rinsho shinkeigaku = Clinical neurology   Vol. 62 ( 9 ) page: 707 - 715   2022.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Clinical Neurology  

    We report a case of left-handed bilingual aphasia with phonemic paraphasia and language mixing from Japanese as a first language to English as a second language. The lesion caused by cerebral infarction was mainly localized in the left parietal lobe white matter. The patient was a 46-year-old, left-handed woman who was bilingual in Japanese and English. Both auditory and visual comprehensions were well maintained after the acute phase of the disease; however, language mixing between Japanese and English was observed during Japanese speech. A pathophysiological interpretation of this case required a focus on the brain network. Our findings suggest that lesions of the superior longitudinal fasciculus and arcuate fasciculus of the white matter fibers just below the left inferior parietal lobule are associated with bilingual aphasia.

    DOI: 10.5692/clinicalneurol.cn-001706

    Scopus

    PubMed

  10. The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

    Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R

    Neuro-oncology     2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/neuonc/noac155

    PubMed

  11. Direct intracranial invasion of eccrine spiradenocarcinoma of the scalp: a case report and literature review.

    Kibe Y, Tanahashi K, Ohtakara K, Okumura Y, Ohka F, Takeuchi K, Nagata Y, Motomura K, Akahori S, Mizuno A, Sasaki H, Shimizu H, Yamaguchi J, Nishikawa T, Yokota K, Saito R

    BMC neurology   Vol. 22 ( 1 ) page: 223   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12883-022-02749-4

    Web of Science

    PubMed

  12. The Aftercare Survey: Assessment and intervention practices after brain tumor surgery in Europe

    Sierpowska Joanna, Rofes Adria, Dahlslatt Kristoffer, Mandonnet Emmanuel, ter Laan Mark, Polczynska Monika, Hamer Philip De Witt, Halaj Matej, Spena Giannantonio, Meling Torstein R., Motomura Kazuya, Reyes Andres Felipe, Campos Alexandre Rainha, Robe Pierre A., Zigiotto Luca, Sarubbo Silvio, Freyschlag Christian F., Broen Martijn P. G., Stranjalis George, Papadopoulos Konstantinos, Liouta Evangelia, Rutten Geert-Jan, Viegas Catarina Pessanha, Silvestre Ana, Perrote Federico, Brochero Natacha, Caceres Cynthia, Zdun-Ryzewska Gata, Kloc Wojciech, Satoer Djaina, Dragoy Olga, Hendriks Marc P. H., Alvarez-Carriles Juan C., Piai Vitoria, Zdun-Ryzewska Agata

    NEURO-ONCOLOGY PRACTICE     2022.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/nop/npac029

    Web of Science

  13. Surgical management of brain metastasis as a part of systematic metastases from adenoid cystic carcinoma of the external auditory canal: illustrative case.

    Kuramitsu S, Motomura K, Nakajima Y, Tsujiuchi T, Motomura A, Matsuo M, Fukaya N, Kageyama A, Kojima I, Ohno M, Saito R

    Journal of neurosurgery. Case lessons   Vol. 3 ( 11 )   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/CASE21673

    PubMed

  14. Serum Concentration of Ropivacaine After Repeated Administration to Several Parts of the Head During Awake Craniotomy: A Prospective Cohort Study.

    Sato T, Ando T, Asano I, Mori A, Motomura K, Nishiwaki K

    Frontiers in medicine   Vol. 9   page: 834334   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmed.2022.834334

    Web of Science

    PubMed

  15. Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions.

    Motomura K, Ohka F, Aoki K, Saito R

    Frontiers in neurology   Vol. 13   page: 874826   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Frontiers in Neurology  

    Gliomas are a category of infiltrating glial neoplasms that are often located within or near the eloquent areas involved in motor, language, and neurocognitive functions. Surgical resection being the first-line treatment for gliomas, plays a crucial role in patient outcome. The role of the extent of resection (EOR) was evaluated, and we reported significant correlations between a higher EOR and better clinical prognosis of gliomas. However, recurrence is inevitable, even after aggressive tumor removal. Thus, efforts have been made to achieve extended tumor resection beyond contrast-enhanced mass lesions in magnetic resonance imaging (MRI)-defined areas, a process known as supratotal resection. Since it has been reported that tumor cells invade beyond regions visible as abnormal areas on MRI, imaging underestimates the true spatial extent of tumors. Furthermore, tumor cells have the potential to spread 10–20 mm away from the MRI-verified tumor boundary. The primary goal of supratotal resection is to maximize EOR and prolong the progression-free and overall survival of patients with gliomas. The available data, as well as our own work, clearly show that supratotal resection of gliomas is a feasible technique that has improved with the aid of awake functional mapping using intraoperative direct electrical stimulation. Awake brain mapping has enabled neurosurgeons achieve supratotal resection with favorable motor, language, and neurocognitive outcomes, ensuring a better quality of life in patients with gliomas.

    DOI: 10.3389/fneur.2022.874826

    Scopus

    PubMed

  16. <sup>11</sup>C-methionine- and <sup>18</sup>F-FDG-PET double-negative metastatic brain tumor from lung adenocarcinoma with paradoxical high <sup>18</sup>F-FDG uptake: A case report.

    Tanahashi K, Hirano M, Chalise L, Tsugawa T, Okumura Y, Hase T, Ohka F, Motomura K, Takeuchi K, Nagata Y, Nakahara N, Hashimoto N, Saito R

    Surgical neurology international   Vol. 13   page: 372   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgical Neurology International  

    Background: Imaging with 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and 11C-methionine (MET)-PET can delineate primary and metastatic brain tumors. Lesion size affects the sensitivity of both scans and histopathological features can also influence FDG-PET, but the effects on MET-PET have not been elucidated. Case Description: We report an unusual case of metastatic brain tumors without accumulation of FDG or MET, contrasting with high FDG uptake in the primary lung lesion. The brain lesions were identified as adenocarcinoma with a more mucus-rich background, contributing to the indistinct accumulation of both FDG and MET. Conclusion: Histopathological characteristics can affect both MET and FDG accumulation, leading to findings contradicting those of the primary lesion.

    DOI: 10.25259/SNI_264_2022

    Scopus

    PubMed

  17. Dural Arteriovenous Fistula Mimicking a Brain Tumor on Methionine-positron Emission Tomography: A Case Report.

    Hanyu T, Nishihori M, Izumi T, Motomura K, Ohka F, Goto S, Araki Y, Yokoyama K, Uda K, Saito R

    NMC case report journal   Vol. 9   page: 289 - 294   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2176/jns-nmc.2022-0055

    PubMed

  18. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.

    Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I

    Brain tumor pathology     2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-021-00418-x

    PubMed

  19. Mathematical modeling and mutational analysis reveal optimal therapy to prevent malignant transformation in grade II IDH-mutant gliomas.

    Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A

    Cancer research     2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/0008-5472.CAN-21-0985

    PubMed

  20. Newly Established Patient-derived Organoid Model of Intracranial Meningioma.

    Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A

    Neuro-oncology     2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/neuonc/noab155

    PubMed

  21. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.

    Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Yamaguchi J, Shimizu H, Wakabayashi T, Saito R

    Journal of neuro-oncology     2021.5

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11060-021-03776-w

    Web of Science

    PubMed

  22. [Lower-grade Gliomas].

    Motomura K

    No shinkei geka. Neurological surgery   Vol. 49 ( 3 ) page: 632 - 639   2021.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11477/mf.1436204437

    PubMed

  23. Survival Benefit of Supratotal Resection in a Long-term Survivor of <i>IDH</i>-wildtype Glioblastoma: A Case Report and Literature Review.

    Yamaguchi J, Motomura K, Ohka F, Aoki K, Tanahashi K, Hirano M, Chalise L, Nishikawa T, Shimizu H, Natsume A, Wakabayashi T, Saito R

    NMC case report journal   Vol. 8 ( 1 ) page: 747 - 753   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2176/nmccrj.cr.2021-0120

    PubMed

  24. Urinary MicroRNA-Based Diagnostic Model for Central Nervous System Tumors Using Nanowire Scaffolds.

    Kitano Y, Aoki K, Ohka F, Yamazaki S, Motomura K, Tanahashi K, Hirano M, Naganawa T, Iida M, Shiraki Y, Nishikawa T, Shimizu H, Yamaguchi J, Maeda S, Suzuki H, Wakabayashi T, Baba Y, Yasui T, Natsume A

    ACS applied materials & interfaces     2021.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1021/acsami.1c01754

    PubMed

  25. Effects of insular resection on interactions between cardiac interoception and emotion recognition.

    Terasawa Y, Motomura K, Natsume A, Iijima K, Chalise L, Sugiura J, Yamamoto H, Koyama K, Wakabayashi T, Umeda S

    Cortex; a journal devoted to the study of the nervous system and behavior   Vol. 137   page: 271 - 281   2021.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Cortex  

    DOI: 10.1016/j.cortex.2021.01.011

    Scopus

    PubMed

  26. <i>Neurod4</i> converts endogenous neural stem cells to neurons with synaptic formation after spinal cord injury.

    Fukuoka T, Kato A, Hirano M, Ohka F, Aoki K, Awaya T, Adilijiang A, Sachi M, Tanahashi K, Yamaguchi J, Motomura K, Shimizu H, Nagashima Y, Ando R, Wakabayashi T, Lee-Liu D, Larrain J, Nishimura Y, Natsume A

    iScience   Vol. 24 ( 2 ) page: 102074   2021.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:iScience  

    DOI: 10.1016/j.isci.2021.102074

    Web of Science

    Scopus

    PubMed

  27. Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery.

    Motomura K, Chalise L, Shimizu H, Yamaguchi J, Nishikawa T, Ohka F, Aoki K, Tanahashi K, Hirano M, Wakabayashi T, Natsume A

    Journal of neurosurgery     page: 1 - 10   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/2020.8.JNS201400

    PubMed

  28. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study. International journal

    Hiroyuki Shimizu, Kazuya Motomura, Fumiharu Ohka, Kosuke Aoki, Kuniaki Tanahashi, Masaki Hirano, Lushun Chalise, Tomohide Nishikawa, Junya Yamaguchi, Jun Yoshida, Atsushi Natsume, Toshihiko Wakabayashi

    Journal of neurosurgery     page: 1 - 9   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The current study aimed to evaluate the treatment outcomes and toxicities of patients with intracranial germ cell tumors (GCTs). METHODS: This study retrospectively included 110 consecutive patients (70 patients in the germinomatous group and 40 patients in the nongerminomatous GCT [NGGCT] groups) receiving surgery, platinum-based chemotherapy, and radiotherapy for newly diagnosed primary intracranial GCTs. In the authors' protocol, patients with GCTs were further divided into the following four groups: the germinomatous group and the NGGCT groups (mature teratoma, intermediate prognosis, or poor prognosis). RESULTS: The median overall survival (OS) and progression-free survival (PFS) rates of the patients in the germinomatous group were significantly higher than those in the NGGCT group (p < 0.001). The 5-, 10-, and 20-year OS rates in the germinomatous group were 97.1%, 95.7%, and 93.2%, respectively, with a median follow-up of 11.0 years. On the contrary, the 5-, 10-, and 20-year OS rates in the NGGCT group were 67.3%, 63.4%, and 55.4%, respectively. The 5-, 10-, and 20-year PFS rates were 91.4%, 86.6%, and 86.6%, respectively, in the germinomatous group, whereas those of the NGGCT group were approximately 67.4%, 60.2%, and 53.5%, respectively. Based on the four types of classification in our study, the 5-, 10-, and 20-year OS rates in the NGGCT intermediate prognosis group were 78.9%, 71.8%, and 53.8%, respectively. On the contrary, the 3- and 5-year OS rates in the NGGCT poor prognosis group were 42.9% and 34.3%, respectively. Moreover, toxicities with the treatment of intracranial GCTs were found to be tolerable in the present study population. The multivariate survival models for OS in the NGGCT intermediate prognosis and poor prognosis groups demonstrated that only the alpha-fetoprotein status was significantly associated with worsened OS (HR 3.88, 95% CI 1.29-11.66; p = 0.02). CONCLUSIONS: The authors found that platinum-based chemotherapy and radiotherapy result in favorable survival outcomes in patients with germinomatous GCTs. Clinical outcomes were still unfavorable in the NGGCT intermediate prognosis and poor prognosis groups; therefore, a new protocol that increases the survival rate of patients belonging in both groups should be considered.

    DOI: 10.3171/2020.6.JNS20638

    PubMed

  29. Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain tumors.

    Motomura K, Takeuchi H, Nojima I, Aoki K, Chalise L, Iijima K, Wakabayashi T, Natsume A

    Scientific reports   Vol. 10 ( 1 ) page: 9044   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-020-65944-8

    PubMed

  30. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. International journal

    Atsushi Natsume, Kosuke Aoki, Fumiharu Ohka, Sachi Maeda, Masaki Hirano, Alimu Adilijiang, Kazuya Motomura, Minako Sumi, Ryo Nishikawa, Yoshitaka Narita, Yoshihiro Muragaki, Takashi Maruyama, Tamio Ito, Takaaki Beppu, Hideo Nakamura, Takamasa Kayama, Shinya Sato, Motoo Nagane, Kazuhiko Mishima, Yoko Nakasu, Kaoru Kurisu, Fumiyuki Yamasaki, Kazuhiko Sugiyama, Takanori Onishi, Yasuo Iwadate, Mizuhiko Terasaki, Hiroyuki Kobayashi, Akira Matsumura, Eiichi Ishikawa, Hikaru Sasaki, Akitake Mukasa, Takayuki Matsuo, Hirofumi Hirano, Toshihiro Kumabe, Nobusada Shinoura, Naoya Hashimoto, Tomokazu Aoki, Akio Asai, Tatsuya Abe, Atsuo Yoshino, Yoshiki Arakawa, Kenichiro Asano, Koji Yoshimoto, Soichiro Shibui, Yusuke Okuno, Toshihiko Wakabayashi

    Journal of neuro-oncology   Vol. 148 ( 1 ) page: 17 - 27   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone. EXPERIMENTAL: DESIGN: Of 122 tumors, we performed deep targeted sequencing to determine the somatic mutations, copy number variations, and tumor mutation burden; pyrosequencing for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation; Sanger sequencing for the telomerase reverse transcriptase (TERT) promoter; and microsatellite instability (MSI) testing in 95, 91, 91 and 72 tumors, respectively. We performed a multivariable Cox regression analysis using backward stepwise selection of variables including clinical factors (sex, age, performance status, residual tumor after resection, tumor location) and genetic alterations. RESULTS: Deep sequencing detected an IDH1 mutation in 13 tumors (14%). The MGMT promoter methylation by quantitative pyrosequencing was observed in 41% of the tumors. A mutation in the TERT promoter was observed in 69% of the tumors. While high tumor mutation burden (> 10 mutations per megabase) was seen in four tumors, none of the tumors displayed MSI-high. The clinical and genetic factors considered as independent favorable prognostic factors were gross total resection (hazard ratio [HR]: 0.49, 95% confidence interval, 0.30-0.81, P = 0.0049) and MGMT promoter methylation (HR: 0.43, 0.21-0.88, P = 0.023). However, tumor location at the temporal lobe (HR: 1.90, 1.22-2.95, P = 0.0046) was an independent unfavorable prognostic factor. No predictive factors specific to the TMZ + IFNβ + Radiotherapy (RT) group were found. CONCLUSION: This additional sub-analytical study of JCOG0911 among patients with newly diagnosed GBM showed that tumor location at the temporal lobe, gross total resection, and MGMT promoter methylation were significant prognostic factors, although no factors specific to IFNβ addition were identified.

    DOI: 10.1007/s11060-020-03505-9

    Web of Science

    Scopus

    PubMed

  31. Trautmann-focused mastoidectomy for a simple, safe presigmoid approach: technical note. International journal

    Kuniaki Tanahashi, Kenji Uda, Yoshio Araki, Kazuhito Takeuchi, Jungsu Choo, Lushun Chalise, Kazuya Motomura, Fumiharu Ohka, Toshihiko Wakabayashi, Atsushi Natsume

    Journal of neurosurgery   Vol. 134 ( 3 ) page: 1 - 5   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The presigmoid approach (PSA) is selected to obtain more lateral access to cerebellopontine angle tumors, brainstem cavernous malformations, or vertebrobasilar artery aneurysms than the standard retrosigmoid approach. However, mastoidectomy for the PSA can be considered time-consuming and to carry a higher risk of complications due to the anatomical complexity of the region. The authors established a method of minimized mastoidectomy focused on exposing Trautmann's triangle as the corridor for the PSA while maximizing procedural simplicity and safety and maintaining a sufficient operative view. The authors present their method of minimized mastoidectomy in a cadaver dissection and operative cases, showing potential as a useful option for the PSA.

    DOI: 10.3171/2020.1.JNS193179

    Scopus

    PubMed

  32. 左前頭弁蓋部病変に対する覚醒下手術後に伝導失語を呈した症例

    澤木 優治, 前澤 聡, 山本 裕泰, 本村 和也, 若林 俊彦

    高次脳機能研究   Vol. 40 ( 1 ) page: 63 - 63   2020.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本高次脳機能障害学会  

  33. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. International journal

    Sachi Maeda, Fumiharu Ohka, Yusuke Okuno, Kosuke Aoki, Kazuya Motomura, Kazuhito Takeuchi, Hironao Kusakari, Nobuyuki Yanagisawa, Shinya Sato, Junya Yamaguchi, Kuniaki Tanahashi, Masaki Hirano, Akira Kato, Hiroyuki Shimizu, Yotaro Kitano, Shintaro Yamazaki, Shinji Yamashita, Hideo Takeshima, Keiko Shinjo, Yutaka Kondo, Toshihiko Wakabayashi, Atsushi Natsume

    Acta neuropathologica communications   Vol. 8 ( 1 ) page: 8 - 8   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Diffuse midline glioma, H3 K27M-mutant is a lethal brain tumor located in the thalamus, brain stem, or spinal cord. H3 K27M encoded by the mutation of a histone H3 gene such as H3F3A plays a pivotal role in the tumorigenesis of this type of glioma. Although several studies have revealed comprehensive genetic and epigenetic profiling, the prognostic factors of these tumors have not been identified to date. In various cancers, oncogenic driver genes have been found to exhibit characteristic copy number alterations termed mutant allele specific imbalance (MASI). Here, we showed that several diffuse midline glioma, H3 K27M-mutant exhibited high variant allele frequency (VAF) of the mutated H3F3A gene using droplet digital polymerase chain reaction (ddPCR) assays. Whole-genome sequencing (WGS) revealed that these cases had various copy number alterations that affected the mutant and/or wild-type alleles of the H3F3A gene. We also found that these MASI cases showed a significantly higher Ki-67 index and poorer survival compared with those in the lower VAF cases (P < 0.05). Our results indicated that the MASI of the H3F3A K27M mutation was associated with the aggressive phenotype of the diffuse midline glioma, H3 K27M-mutant via upregulation of the H3 K27M mutant protein, resulting in downregulation of H3K27me3 modification.

    DOI: 10.1186/s40478-020-0882-4

    Web of Science

    Scopus

    PubMed

  34. Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and <i>IDH2</i>-mutant anaplastic oligodendroglioma: a case report and literature review. International journal

    Shimizu H, Motomura K, Ohka F, Aoki K, Tanahashi K, Hirano M, Chalise L, Nishikawa T, Yamaguchi J, Wakabayashi T, Natsume A

    Neuro-oncology advances   Vol. 2 ( 1 ) page: vdaa101   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/noajnl/vdaa101

    PubMed

  35. Preoperative predictive factors affecting return to work in patients with gliomas undergoing awake brain mapping.

    Yoshida A, Motomura K, Natsume A, Chalise L, Iijima K, Hara D, Kadono I, Wakai K, Wakabayashi T

    Journal of neuro-oncology     2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11060-019-03371-0

    PubMed

  36. Long-Term Survival in Patients with Primary Intracranial Germ Cell Tumors Treated with Surgery, Carboplatin based Chemotherapy Followed by Radiotherapy International journal

    Motomura K., Natsume A., Wakabayashi T.

    PEDIATRIC BLOOD & CANCER   Vol. 66   page: S67 - S67   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  37. AN INTEGRATED APPROACH COMBINING MATHEMATICAL AND GENOMIC METHODS TO REVEAL THE OPTIMAL TIMING OF THERAPEUTIC INTERVENTION IN WHO GRADE II DIFFUSE GLIOMA International journal

    Aoki Kosuke, Yamamoto Takashi, Suzuki Hiromichi, Maeda Sachi, Ranjit Melissa, Motomura Kazuya, Nakamura Hideo, Narita Yoshitaka, Nakada Mitsutoshi, Deguchi Shoichi, Mizoguchi Masahiro, Momii Yasutomo, Muragaki Yoshihiro, Abe Tatsuya, Akimoto Jiro, Wakabayashi Toshihiko, Haeno Hiroshi, Natsume Atsushi

    NEURO-ONCOLOGY   Vol. 21   page: 270 - 270   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  38. MACHINE LEARNING TO DETECT GLIOMAS IN URINE-BASED LIQUID BIOPSY International journal

    Kitano Yotaro, Aoki Kosuke, Yasui Takao, Motomura Kazuya, Ohka Fumiharu, Tanahashi Kuniaki, Hirano Masaki, Nishikawa Tomohide, Shimizu Hiroyuki, Yamaguchi Junya, Maeda Sachi, Yamazaki Shintaro, Wakabayashi Toshihiko, Natsume Atsushi

    NEURO-ONCOLOGY   Vol. 21   page: 151 - 151   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  39. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.

    Adilijiang A, Hirano M, Okuno Y, Aoki K, Ohka F, Maeda S, Tanahashi K, Motomura K, Shimizu H, Yamaguchi J, Wakabayashi T, Natsume A

    Molecules (Basel, Switzerland)   Vol. 24 ( 17 )   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/molecules24173046

    PubMed

  40. Spontaneous tumor regression of intracranial solitary fibrous tumor originating from the medulla oblongata: A case report and literature review.

    Yamaguchi J, Motomura K, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Wakabayashi T, Natsume A

    World neurosurgery     2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.wneu.2019.07.052

    PubMed

  41. Anterior insular cortex stimulation and its effects on emotion recognition.

    Motomura K, Terasawa Y, Natsume A, Iijima K, Chalise L, Sugiura J, Yamamoto H, Koyama K, Wakabayashi T, Umeda S

    Brain structure & function     2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00429-019-01895-9

    PubMed

  42. Posterior Cerebral Artery Reconstruction by In-Situ Bypass with Superior Cerebellar Artery via Occipital Transtentorial Approach. International journal

    Kuniaki Tanahashi, Yoshio Araki, Kenji Uda, Shinsuke Muraoka, Kazuya Motomura, Chalise Lushun, Toshihiko Wakabayashi, Atsushi Natsume

    World neurosurgery   Vol. 126   page: 24 - 29   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Posterior cerebral artery (PCA) aneurysms are relatively rare, and neck clipping is often difficult due to their fusiform shape. We report a case of a thrombosed aneurysm of the distal PCA for which curative trapping and parent artery reconstruction by in situ bypass were performed through an occipital transtentorial approach (OTA). CASE DESCRIPTION: A 67-year-old woman had been suffering from numbness in the right face and limbs for 4 months. Radiologic imaging demonstrated a thrombosed aneurysm on a distal portion of the left PCA. Curative trapping of the aneurysm and in-situ bypass between the distal PCA and superior cerebellar artery were performed through the OTA. Before surgery, we had evaluated access to the PCA and feasibility of the bypass in a cadaveric simulation. The PCA was well exposed in the posterior half of the ambient cistern, and the proximity of the distal PCA to the superior cerebellar artery through a tentorial incision was confirmed. CONCLUSIONS: This OTA could represent a useful option for definitive treatment of distal PCA aneurysms.

    DOI: 10.1016/j.wneu.2019.02.127

    Web of Science

    Scopus

    PubMed

  43. Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping.

    Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Yamaguchi J, Shimizu H, Wakabayashi T, Natsume A

    Journal of neurosurgery     page: 1-9   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/2019.3.JNS19211

    PubMed

  44. Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma.

    Ranjit M, Hirano M, Aoki K, Okuno Y, Ohka F, Yamamichi A, Kato A, Maeda S, Motomura K, Matsuo K, Enomoto A, Ino Y, Todo T, Takahashi M, Wakabayashi T, Kato T, Natsume A

    Cell reports   Vol. 26 ( 9 ) page: 2274-2281.e5   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.celrep.2019.01.109

    PubMed

  45. A mathematical model for predicting the optimal timing of treatment to minimize the malignant transformation rate in WHO grade II diffuse glioma

    Aoki Kousuke, Motomura Kazuya, Nakamura Hideo, Narita Yoshitaka, Yoshimoto Koji, Momii Yasutomo, Muragaki Yoshihiro, Wakabayashi Toshihiko, Haeno Hiroshi, Natsume Atsushi

    BRAIN PATHOLOGY   Vol. 29   page: 67-68   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  46. Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions.

    Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Wakabayashi T, Natsume A

    World neurosurgery   Vol. 119   page: 30-39   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.wneu.2018.07.193

    PubMed

  47. Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors.

    Motomura K, Sumita K, Chalise L, Nishikawa T, Tanahashi K, Ohka F, Aoki K, Hirano M, Nakamura T, Matsushita T, Wakabayashi T, Natsume A

    World neurosurgery   Vol. 119   page: e1052-e1059   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.wneu.2018.08.039

    PubMed

  48. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.

    Wee CW, Kim IH, Park CK, Kim JW, Dho YS, Ohka F, Aoki K, Motomura K, Natsume A, Kim N, Suh CO, Chang JH, Kim SH, Cho WK, Lim DH, Nam DH, Choi JW, Kim IA, Kim CY, Oh YT, Cho O, Chung WK, Kim SH, Kim E

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology     2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2018.09.001

    PubMed

  49. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.

    Hirano M, Ohka F, Maeda S, Chalise L, Yamamichi A, Aoki K, Kato A, Tanahashi K, Motomura K, Nishimura Y, Hara M, Shinjo K, Kondo Y, Wakabayashi T, Natsume A

    Brain tumor pathology   Vol. 35 ( 2 ) page: 97-105   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-018-0310-7

    PubMed

  50. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

    Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A

    Brain tumor pathology   Vol. 35 ( 2 ) page: 106-113   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-018-0312-5

    PubMed

  51. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas International journal

    Kosuke Aoki, Hideo Nakamura, Hiromichi Suzuki, Keitaro Matsuo, Keisuke Kataoka, Teppei Shimamura, Kazuya Motomura, Fumiharu Ohka, Satoshi Shiina, Takashi Yamamoto, Yasunobu Nagata, Tetsuichi Yoshizato, Masahiro Mizoguchi, Tatsuya Abe, Yasutomo Momii, Yoshihiro Muragaki, Reiko Watanabe, Ichiro Ito, Masashi Sanada, Hironori Yajima, Naoya Morita, Ichiro Takeuchi, Satoru Miyano, Toshihiko Wakabayashi, Seishi Ogawa, Atsushi Natsume

    Neuro-Oncology   Vol. 20 ( 1 ) page: 66 - 77   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press  

    Background Diffuse lower-grade gliomas (LGGs) are genetically classified into 3 distinct subtypes based on isocitrate dehydrogenase (IDH) mutation status and codeletion of chromosome 1p and 19q (1p/19q). However, the subtype-specific effects of additional genetic lesions on survival are largely unknown. Methods Using Cox proportional hazards regression modeling, we investigated the subtype-specific effects of genetic alterations and clinicopathological factors on survival in each LGG subtype, in a Japanese cohort of LGG cases fully genotyped for driver mutations and copy number variations associated with LGGs (n = 308). The results were validated using a dataset from 414 LGG cases available from The Cancer Genome Atlas (TCGA). Results In Oligodendroglioma, IDH-mutant and 1p/19q codeleted, NOTCH1 mutations (P = 0.0041) and incomplete resection (P = 0.0019) were significantly associated with shorter survival. In Astrocytoma, IDH-mutant, PIK3R1 mutations (P = 0.0014) and altered retinoblastoma pathway genes (RB1, CDKN2A, and CDK4) (P = 0.013) were independent predictors of poor survival. In IDH-wildtype LGGs, co-occurrence of 7p gain, 10q loss, mutation in the TERT promoter (P = 0.024), and grade III histology (P &lt
    0.0001) independently predicted poor survival. IDH-wildtype LGGs without any of these factors were diagnosed at a younger age (P = 0.042), and were less likely to have genetic lesions characteristic of glioblastoma, in comparison with other IDH-wildtype LGGs, suggesting that they likely represented biologically different subtypes. These results were largely confirmed in the cohort of TCGA. Conclusions Subtype-specific genetic lesions can be used to stratify patients within each LGG subtype. enabling better prognostication and management.

    DOI: 10.1093/neuonc/nox132

    Web of Science

    Scopus

    PubMed

  52. Does ATRX immunohistochemistry deserve a surrogate of 1p/19q codel in grade II, III gliomas? Reviewed

    Yamamichi Akane, Ohka Fumiharu, Aoki Kosuke, Suzuki Hiromichi, Hirano Masaki, Motomura Kazuya, Wakabayashi Toshihiko, Kato Yukinari, Natsume Atsushi

    CANCER SCIENCE   Vol. 109   page: 926   2018.1

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  53. Remote ischemic preconditioning protects human neural stem cells from oxidative stress. International journal

    Ayako Motomura, Mikiko Shimizu, Akira Kato, Kazuya Motomura, Akane Yamamichi, Hiroko Koyama, Fumiharu Ohka, Tomohide Nishikawa, Yusuke Nishimura, Masahito Hara, Tetsuya Fukuda, Yasuhiko Bando, Toshihide Nishimura, Toshihiko Wakabayashi, Atsushi Natsume

    Apoptosis : an international journal on programmed cell death   Vol. 22 ( 11 ) page: 1353 - 1361   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    In previous clinical trials, we showed that remote ischemic preconditioning (rIPC) reduced myocardial damage in children undergoing treatment for congenital heart defects and postoperative renal failure in patients undergoing abdominal aortic aneurysm surgery. In rabbit experiments, pre-treatment with plasma and plasma dialysate (obtained using 15-kDa cut-off dialysis membrane) from donor rabbits subjected to rIPC similarly protected against cardiac infarction. However, the protective substances containing in rIPC plasma have been unknown. In the present study, we showed that rIPC plasma exerted anti-apoptotic and anti-oxidative effects on human neural stem cells under oxygen glucose deprivation (OGD) that mimics brain ischemia. Additionally, we applied the sample to the liquid chromatography integrated with mass spectrometry to identify candidate key molecules in the rIPC plasma and determine its role in protecting neural stem cells from OGD-induced cell death. Thioredoxin increased significantly after rIPC compared to pre-IPC. Pretreatment with thioredoxin, the antioxidant protein, markedly protected human neural stem cells from OGD-induced cell death. The effect of thioredoxin on brain ischemia in animals should be further evaluated. However, the present study first evaluated the effect of rIPC in the ischemic cellular model.

    DOI: 10.1007/s10495-017-1425-8

    Web of Science

    Scopus

    PubMed

  54. Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas associated with eloquent areas. International journal

    Kazuya Motomura, Atsushi Natsume, Kentaro Iijima, Shunichiro Kuramitsu, Masazumi Fujii, Takashi Yamamoto, Satoshi Maesawa, Junko Sugiura, Toshihiko Wakabayashi

    Journal of neurosurgery   Vol. 127 ( 4 ) page: 790 - 797   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC NEUROLOGICAL SURGEONS  

    OBJECTIVE Maximum extent of resection (EOR) for lower-grade and high-grade gliomas can increase survival rates of patients. However, these infiltrative gliomas are often observed near or within eloquent regions of the brain. Awake surgery is of known benefit for the treatment of gliomas associated with eloquent regions in that brain function can be preserved. On the other hand, intraoperative MRI (iMRI) has been successfully used to maximize the resection of tumors, which can detect small amounts of residual tumors. Therefore, the authors assessed the value of combining awake craniotomy and iMRI for the resection of brain tumors in eloquent areas of the brain. METHODS The authors retrospectively reviewed the records of 33 consecutive patients with glial tumors in the eloquent brain areas who underwent awake surgery using iMRI. Volumetric analysis of MRI studies was performed. The pre-, intra-, and postoperative tumor volumes were measured in all cases using MRI studies obtained before, during, and after tumor resection. RESULTS Intraoperative MRI was performed to check for the presence of residual tumor during awake surgery in a total of 25 patients. Initial iMRI confirmed no further tumor resection in 9 patients (36%) because all observable tumors had already been removed. In contrast, intraoperative confirmation of residual tumor during awake surgery led to further tumor resection in 16 cases (64%) and eventually an EOR of more than 90% in 8 of 16 cases (50%). Furthermore, EOR benefiting from iMRI by more than 15% was found in 7 of 16 cases (43.8%). Interestingly, the increase in EOR as a result of iMRI for tumors associated mainly with the insular lobe was significantly greater, at 15.1%, than it was for the other tumors, which was 8.0% (p = 0.001). CONCLUSIONS This study revealed that combining awake surgery with iMRI was associated with a favorable surgical outcome for intrinsic brain tumors associated with eloquent areas. In particular, these benefits were noted for patients with tumors with complex anatomy, such as those associated with the insular lobe.

    DOI: 10.3171/2016.9.JNS16152

    Web of Science

    Scopus

    PubMed

  55. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. International journal

    Lushun Chalise, Kazuya Motomura, Fumiharu Ohka, Masaki Hirano, Masahito Hara, Yusuke Nishimura, Atsushi Natsume, Toshihiko Wakabayashi

    Anticancer research   Vol. 37 ( 9 ) page: 5215 - 5223   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:INT INST ANTICANCER RESEARCH  

    BACKGROUND/AIM: In the current study, we aimed to compare DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy with high-dose methotrexate (HD-MTX) monotherapy plus whole-brain radiation therapy (WBRT) for newly-diagnosed primary central nervous system lymphoma (PCNSL), in terms of their efficacies and tolerability. PATIENTS AND METHODS: A total of 21 consecutive patients with PCNSL were treated with DeVIC therapy and WBRT, between 2002 and 2010. From 2010 to 2014, 14 consecutive patients with PCNSL were treated with HD-MTX followed by WBRT. RESULTS: Overall response rates of complete and partial response for initial chemotherapy were significantly better with DeVIC therapy (95.2%) than with HD-MTX monotherapy (50%). Furthermore, one-year and two-year progression-free survival (PFS) rates were better in the DeVIC cohort than in the HD-MTX cohort. DeVIC therapy yielded higher early response rates, longer PFS, and manageable adverse events, and may be potentially better for the treatment of cases that are refractory to MTX-based therapy. CONCLUSION: Our retrospective clinical study revealed that DeVIC therapy is comparable with that of HD-MTX monotherapy plus WBRT, for newly diagnosed PCNSL.

    DOI: 10.21873/anticanres.11945

    Web of Science

    Scopus

    PubMed

  56. Pathogenesis of diffuse low-grade gliomas

    Pendleton C, Motomura K

    Diffuse Low-Grade Gliomas in Adults     page: 111 - 117   2017.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Diffuse Low-Grade Gliomas in Adults  

    DOI: 10.1007/978-3-319-55466-2_6

    Scopus

  57. Distribution of norovirus genotypes and subtypes in river water by ultra-deep sequencing-based analysis

    Boonchan M

    Letters in Applied Microbiology   Vol. 65 ( 1 ) page: 98 - 104   2017.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Letters in Applied Microbiology  

    DOI: 10.1111/lam.12750

    Scopus

  58. Corrigendum: Girdin maintains the stemness of glioblastoma stem cells (Oncogene (2012) 31 (2715-2724) DOI: 10.1038/onc.2011.466) Reviewed

    A. Natsume, T. Kato, S. Kinjo, A. Enomoto, H. Toda, S. Shimato, F. Ohka, K. Motomura, Y. Kondo, T. Miyata, M. Takahashi, T. Wakabayashi

    Oncogene   Vol. 31 ( 22 ) page: 2715 - 2724   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nature Publishing Group  

    Glioblastomas (GBMs) are the most common and aggressive type of brain tumor. GBMs usually show hyperactivation of the PI3K-Akt pathway, a pro-tumorigenic signaling cascade that contributes to pathogenesis. Girdin, an actin-binding protein identified as a novel substrate of Akt, regulates the sprouting of axons and the migration of neural progenitor cells during early postnatal-stage neurogenesis in the hippocampus. Here, we show that Girdin is highly expressed in human glioblastoma (GBM). Stable Girdin knockdown in isolated GBM stem cells resulted in decreased expression of stem cell markers, including CD133, induced multilineage neural differentiation, and inhibited in vitro cell motility, ex vivo invasion, sphere-forming capacity and in vivo tumor formation. Furthermore, exogenous expression of the Akt-binding domain of Girdin, which competitively inhibits its Akt-mediated phosphorylation, diminished the expression of stem cell markers, SOX2 and nestin, and migration on the brain slice and induced the expression of neural differentiation markers glial fibrillary acidic protein/ΒIII Tubulin. Our results reveal that Girdin is required for GBM-initiating stem cells to sustain the stemness and invasive properties. © 2012 Macmillan Publishers Limited All rights reserved.

    DOI: 10.1038/onc.2011.466

    Scopus

  59. Girdin maintains the stemness of glioblastoma stem cells (vol 31, pg 2715, 2012) Reviewed

    A. Natsume, T. Kato, S. Kinjo, A. Enomoto, H. Toda, S. Shimato, F. Ohka, K. Motomura, Y. Kondo, T. Miyata, M. Takahashi, T. Wakabayashi

    ONCOGENE   Vol. 36 ( 26 ) page: 3796 - 3796   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    DOI: 10.1038/onc.2017.17

    Web of Science

    PubMed

  60. A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma.

    Fumiharu Ohka, Akane Yamamichi, Michihiro Kurimoto, Kazuya Motomura, Kuniaki Tanahashi, Hiromichi Suzuki, Kosuke Aoki, Shoichi Deguchi, Lushun Chalise, Masaki Hirano, Akira Kato, Yusuke Nishimura, Masahito Hara, Yukinari Kato, Toshihiko Wakabayashi, Atsushi Natsume

    Brain tumor pathology   Vol. 34 ( 2 ) page: 91 - 97   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    IDH1 gene mutation has been demonstrated to be an oncogenic driver in a majority of lower-grade gliomas (LGGs). In contrast to other central nervous neoplasms and normal brain tissue without IDH1 mutation, almost 80% of LGGs exhibit IDH1 mutation. Therefore, expeditious detection of IDH1 mutation is useful, not only for intraoperative diagnosis of these gliomas but also for determination of the border between the tumor and normal brain tissue. In this study, we established a rapid genotyping assay with a simple DNA extraction method, involving only incubation of the tumor specimen with Tris-EDTA buffer, which can be easily performed in an operating room. In all 11 tested cases, we could identify the IDH1 status within 90-100 min intraoperatively. In a case of anaplastic astrocytoma, IDH-mutant, we could detect the tumor border by IDH1 profiling. In addition, with this assay, we could detect IDH1 mutation using cell-free tumor DNA derived from cerebrospinal fluid in a case of glioblastoma, IDH-mutant. Considering that clinical trials of mutated IDH1 inhibitors are ongoing, less-invasive intraoperative IDH1 gene profiling might be useful for decision making of the overall treatment strategy of LGGs. Our assay might be a useful tool for precision medicine and surgery of IDH1-mutant gliomas.

    DOI: 10.1007/s10014-017-0281-0

    Web of Science

    Scopus

    PubMed

  61. Efficacy of the transtemporal approach with awake brain mapping to reach the dominant posteromedial temporal lesions. International journal

    Kentaro Iijima, Kazuya Motomura, Lushun Chalise, Masaki Hirano, Atsushi Natsume, Toshihiko Wakabayashi

    Acta neurochirurgica   Vol. 159 ( 1 ) page: 177 - 184   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER WIEN  

    BACKGROUND: Surgeries for lesions in the dominant hippocampal and parahippocampal gyrus involving the posteromedial temporal regions are challenging to perform because they are located close to Wernicke's area; white matter fibers related with language; the optic radiations; and critical neurovascular structures. We performed a transtemporal approach with awake functional mapping for lesions affecting the dominant posteromedial temporal regions. The aim of this study was to assess the feasibility, safety, and efficacy of awake craniotomy for these lesions. METHODS: We retrospectively reviewed four consecutive patients with tumors or cavernous angiomas located in the left hippocampal and parahippocampal gyrus, which further extended to the posteromedial temporal regions, who underwent awake surgery between December 2014 and January 2016. RESULTS: Four patients with lesions associated with the left hippocampal and parahippocampal gyrus, including the posteromedial temporal area, who underwent awake surgery were registered in the study. In all four patients, cortical and subcortical eloquent areas were identified via direct electrical stimulation. This allowed determination of the optimal surgical route to the angioma or tumor, even in the language-dominant hippocampal and parahippocampal gyrus. In particular, this approach enabled access to the upper part of posteromedial temporal lesions, while protecting the subcortical language-related fibers, such as the superior longitudinal fasciculus. CONCLUSIONS: This study revealed that awake brain mapping can enable the safe resection of dominant posteromedial temporal lesions, while protecting cortical and subcortical eloquent areas. Furthermore, our experience with four patients demonstrates the feasibility, safety, and efficacy of awake surgery for these lesions.

    DOI: 10.1007/s00701-016-3035-6

    Web of Science

    Scopus

    PubMed

  62. Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.

    Kuramitsu S, Yamamichi A, Ohka F, Motomura K, Hara M, Natsume A

    Immunotherapy   Vol. 8 ( 12 ) page: 1393-1404   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2217/imt-2016-0076

    PubMed

  63. [Update Knowledge for Brain Tumors(9)Peripheral Nerve Tumor].

    Motomura K, Chalise L

    No shinkei geka. Neurological surgery   Vol. 44 ( 8 ) page: 699-709   2016.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11477/mf.1436203357

    PubMed

  64. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.

    Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A

    Cancer immunology research   Vol. 4 ( 3 ) page: 259-68   2016.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/2326-6066.CIR-15-0060

    PubMed

  65. An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.

    Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto M, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Hara M, Wakabayashi T, Baba Y, Kato Y, Natsume A

    Science and technology of advanced materials   Vol. 17 ( 1 ) page: 618-625   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/14686996.2016.1227222

    PubMed

  66. Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.

    Kurimoto M, Suzuki H, Aoki K, Ohka F, Kondo G, Motomura K, Iijima K, Yamamichi A, Ranjit M, Wakabayashi T, Kimura S, Natsume A

    Cancer investigation   Vol. 34 ( 1 ) page: 12-5   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/07357907.2015.1084001

    PubMed

  67. Applicable advances in the molecular pathology of glioblastoma.

    Ranjit M, Motomura K, Ohka F, Wakabayashi T, Natsume A

    Brain tumor pathology   Vol. 32 ( 3 ) page: 153-62   2015.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-015-0224-6

    PubMed

  68. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.

    Tanahashi K, Natsume A, Ohka F, Motomura K, Alim A, Tanaka I, Senga T, Harada I, Fukuyama R, Sumiyoshi N, Sekido Y, Wakabayashi T

    Journal of neuropathology and experimental neurology   Vol. 74 ( 7 ) page: 704-9   2015.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/NEN.0000000000000211

    PubMed

  69. Intraoperative subcortical mapping of a language-associated deep frontal tract connecting the superior frontal gyrus to Broca's area in the dominant hemisphere of patients with glioma.

    Fujii M, Maesawa S, Motomura K, Futamura M, Hayashi Y, Koba I, Wakabayashi T

    Journal of neurosurgery   Vol. 122 ( 6 ) page: 1390-6   2015.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/2014.10.JNS14945

    PubMed

  70. Mutational landscape and clonal architecture in grade II and III gliomas.

    Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S

    Nature genetics   Vol. 47 ( 5 ) page: 458-68   2015.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/ng.3273

    PubMed

  71. Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report.

    Kuramitsu S, Motomura K, Natsume A, Wakabayashi T

    NMC case report journal   Vol. 2 ( 1 ) page: 40-45   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2176/nmccrj.2014-0025

    PubMed

  72. Evaluation of resting state networks in patients with gliomas: connectivity changes in the unaffected side and its relation to cognitive function.

    Maesawa S, Bagarinao E, Fujii M, Futamura M, Motomura K, Watanabe H, Mori D, Sobue G, Wakabayashi T

    PloS one   Vol. 10 ( 2 ) page: e0118072   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0118072

    PubMed

  73. Association of dorsal inferior frontooccipital fasciculus fibers in the deep parietal lobe with both reading and writing processes: a brain mapping study.

    Motomura K, Fujii M, Maesawa S, Kuramitsu S, Natsume A, Wakabayashi T

    Journal of neurosurgery   Vol. 121 ( 1 ) page: 142-8   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3171/2014.2.JNS131234

    PubMed

  74. Lack of presence of the human cytomegalovirus in human glioblastoma.

    Yamashita Y, Ito Y, Isomura H, Takemura N, Okamoto A, Motomura K, Tsujiuchi T, Natsume A, Wakabayashi T, Toyokuni S, Tsurumi T

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   Vol. 27 ( 7 ) page: 922-9   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/modpathol.2013.219

    PubMed

  75. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

    Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A

    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine   Vol. 35 ( 6 ) page: 5911-20   2014.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s13277-014-1784-5

    PubMed

  76. Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma.

    Ando H, Natsume A, Senga T, Watanabe R, Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, Ito M, Saito K, Morgan R, Wakabayashi T

    Cancer chemotherapy and pharmacology   Vol. 73 ( 1 ) page: 53-60   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00280-013-2316-5

    PubMed

  77. Assessment of tumor cells in a mouse model of diffuse infiltrative glioma by Raman spectroscopy.

    Tanahashi K, Natsume A, Ohka F, Momota H, Kato A, Motomura K, Watabe N, Muraishi S, Nakahara H, Saito Y, Takeuchi I, Wakabayashi T

    BioMed research international   Vol. 2014   page: 860241   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1155/2014/860241

    PubMed

  78. Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.

    Tsujiuchi T, Natsume A, Motomura K, Kondo G, Ranjit M, Hachisu R, Sugimura I, Tomita S, Takehara I, Woolley M, Barua NU, Gill SS, Bienemann AS, Yamashita Y, Toyokuni S, Wakabayashi T

    American journal of translational research   Vol. 6 ( 2 ) page: 169-78   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PubMed

  79. PDGFRA gain in low-grade diffuse gliomas.

    Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Nonoguchi N, Pierscianek D, Kim YH, Mariani L, Vital A, Perry A, Ohgaki H

    Journal of neuropathology and experimental neurology   Vol. 72 ( 1 ) page: 61-6   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/NEN.0b013e31827c4b5b

    PubMed

  80. MET gain in diffuse astrocytomas is associated with poorer outcome.

    Pierscianek D, Kim YH, Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Wrede K, Nakazato Y, Tanaka Y, Mariani L, Vital A, Sure U, Ohgaki H

    Brain pathology (Zurich, Switzerland)   Vol. 23 ( 1 ) page: 13-8   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1750-3639.2012.00609.x

    PubMed

  81. Interferon-β delivery via human neural stem cell abates glial scar formation in spinal cord injury.

      Vol. 22 ( 12 ) page: 2187-201   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3727/096368912X657882

    PubMed

  82. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.

    Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayashi T

    Cancer science   Vol. 103 ( 10 ) page: 1871-9   2012.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1349-7006.2012.02377.x

    PubMed

  83. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.

    Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Pierscianek D, Kim YH, Mariani L, Vital A, Ohgaki H

    Journal of neuropathology and experimental neurology   Vol. 71 ( 8 ) page: 702-7   2012.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/NEN.0b013e31825f2e5d

    PubMed

  84. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.

    Kishida Y, Natsume A, Toda H, Toi Y, Motomura K, Koyama H, Matsuda K, Nakayama O, Sato M, Suzuki M, Kondo Y, Wakabayashi T

    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine   Vol. 33 ( 2 ) page: 373-81   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s13277-012-0319-1

    PubMed

  85. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.

    Motomura K, Natsume A, Wakabayashi T

    Journal of neuro-oncology   Vol. 106 ( 1 ) page: 209-11   2012.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11060-011-0651-0

    PubMed

  86. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.

    Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T

    Leukemia & lymphoma   Vol. 52 ( 11 ) page: 2069-75   2011.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/10428194.2011.596967

    PubMed

  87. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

      Vol. 117 ( 8 ) page: 1721-30   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cncr.25637

    PubMed

  88. Glioma-initiating cells and molecular pathology: implications for therapy.

    Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, Iwami K, Wakabayashi T

    Brain tumor pathology   Vol. 28 ( 1 ) page: 1-12   2011.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-010-0011-3

    PubMed

  89. Rhabdoid glioblastoma in a child: case report and literature review.

    Momota H, Iwami K, Fujii M, Motomura K, Natsume A, Ogino J, Hasegawa T, Wakabayashi T

    Brain tumor pathology   Vol. 28 ( 1 ) page: 65-70   2011.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10014-010-0010-4

    PubMed

  90. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

    Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T

    PloS one   Vol. 6 ( 8 ) page: e23332   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0023332

    PubMed

  91. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.

    Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, Toi Y, Ito M, Motomura K, Yoshida J, Yoshikawa K, Wakabayashi T

    Cancer science   Vol. 101 ( 12 ) page: 2518-24   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1349-7006.2010.01734.x

    PubMed

  92. A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation.

    Motomura K, Ogura M, Natsume A, Yokoyama H, Wakabayashi T

    Neuroscience letters   Vol. 485 ( 1 ) page: 65-70   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.neulet.2010.08.065

    PubMed

  93. [The genome atlas of brain tumors].

    Natsume A, Motomura K, Wakabayashi T

    Nihon rinsho. Japanese journal of clinical medicine   Vol. 68 Suppl 8   page: 473-80   2010.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    PubMed

  94. Epigenetic aberrations and therapeutic implications in gliomas.

    Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T, Yoshida J

    Cancer science   Vol. 101 ( 6 ) page: 1331-6   2010.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1349-7006.2010.01545.x

    PubMed

  95. The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.

    Ohno M, Natsume A, Kondo Y, Iwamizu H, Motomura K, Toda H, Ito M, Kato T, Wakabayashi T

    Molecular cancer research : MCR   Vol. 7 ( 12 ) page: 2022-30   2009.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/1541-7786.MCR-09-0319

    PubMed

▼display all

Books 20

  1. ペランパネルによるてんかん治療のストラテジー第2版:てんかん患者における周術期管理の実際

    本村和也、齋藤竜太

    先端医学社  2022.9 

     More details

    Total pages:175   Responsible for pages:114-118   Language:Japanese Book type:Textbook, survey, introduction

  2. 生体の科学:覚醒下手術による感情認識に関わる島皮質機能の解明~脳と心の脳神経外科学・認知神経科学の融合型研究~ Reviewed

    本村和也、寺澤悠理、梅田聡( Role: Contributor)

    医学書院  2021.10 

     More details

    Total pages:502   Responsible for pages:461-463   Language:Japanese

  3. 術中神経モニタリングバイブル 改訂版

    本村和也( Role: Joint author)

    羊土社  2020.11 

     More details

    Language:Japanese

  4. Medical Technology: この1冊で安心!周術期の生理機能検査 丸ごとガイド; 頭蓋内腫瘍の周術期MRI検査

    本村和也( Role: Joint author)

    医歯薬出版株式会社  2019.12 

     More details

    Responsible for pages:1508-1514   Language:Japanese Book type:Scholarly book

  5. 覚醒下手術によるsupratotal resectionを目指したlower grade gliomaに対する手術戦略

    本村和也( Role: Sole author)

    脳神経外科速報  2019.8 

     More details

    Language:Japanese

  6. 覚醒下腫瘍摘出術と機能評価

    本村和也、夏目敦至、若林俊彦( Role: Sole author)

    リハビリテーション医学誌  2019.8 

     More details

    Language:Japanese

  7. ニューロナビゲーションシステム;OPERADA Arrowの脳腫瘍手術における臨床使用経験

    本村和也、若林俊彦( Role: Sole author)

    MEDIX  2019.6 

     More details

    Language:Japanese

  8. Diffuse Low-Grade Gliomas in Adults, Pathogenesis of Diffuse low-grade gliomas

    Courtney Pendleton, Kazuya Motomura, Atsushi Natsume( Role: Joint author)

    Springer  2017 

     More details

    Language:English Book type:Scholarly book

  9. 脳腫瘍臨床病理カラーアトラス 第4版; 神経線維腫、神経周膜腫、混成神経鞘腫瘍

    本村和也( Role: Joint author)

    医学書院  2017.10 

     More details

    Language:Japanese Book type:Scholarly book

  10. 耳鼻咽喉科・頭頚部外科 聴神経腫瘍の臨床像と鑑別診断

    本村和也、棚橋邦明、夏目敦至、曾根三千彦( Role: Joint author)

    日本臨床  2016.12 

     More details

    Language:Japanese Book type:Scholarly book

  11. 脳神経外科・脳腫瘍学・術中MRIを用いた画像誘導手術

    本村和也( Role: Joint author)

    日本臨床  2016.9 

     More details

    Language:Japanese Book type:Scholarly book

  12. 脳腫瘍Update (9)脳神経・脊髄神経腫瘍

    本村和也( Role: Joint author)

    医学書院  2016.8 

     More details

    Language:Japanese Book type:Scholarly book

  13. 脳神経外科レジデントマニュアル

    本村和也( Role: Joint author)

    医学書院  2016.5 

     More details

    Language:Japanese Book type:Scholarly book

  14. 脳神経外科学 改訂12版 -脳腫瘍・血管芽腫-

    本村和也( Role: Joint author)

    京都  2016.3 

     More details

    Language:Japanese

  15. 高齢者の悪性神経膠腫の治療の現状

    若林俊彦、本村和也、大岡史治( Role: Joint author)

    Geriatric neurosurgery  2016 

     More details

    Language:Japanese

  16. Clinical Neuroscience 言語の起源と脳の進化、識字の神経基盤、

    本村和也( Role: Sole author)

    中外医学社  2015.9 

     More details

    Language:Japanese

  17. 膠芽腫のDNAメチル化とInterferon-β療法―INTEGRA study

    本村和也、夏目敦至、若林俊彦( Role: Joint author)

    中外医学社  2015.1 

     More details

    Language:Japanese

  18. 神経症候群Ⅲ-その他の神経疾患を含めて-  脳梁部・視床部・視床下部・基底核部の腫瘍(脳室腫瘍を除く)

    本村和也、夏目敦至、若林俊彦( Role: Joint author)

    日本臨床  2014.6 

     More details

    Language:Japanese

  19. 神経モニタリングポケットマニュアル

    本村和也( Role: Joint author)

    羊土社  2014.6 

     More details

    Language:Japanese

  20. Tumors of the Central Nervous System Volume 2; Glioma-Initiating Cells: Interferon Treatment.

    Atsushi Natsume, Masasuke Ohno, Kanako Yuki, Kazuya Motomura, Toshihiko Wakabayashi( Role: Joint author)

    Springer  2011 

     More details

    Total pages:458   Responsible for pages:269-276   Language:English

▼display all

MISC 22

  1. ROLE OF CD79B Y196 MUTATION IN PCNSL AS A POTENT PREDICTIVE MARKER FOR FAVORABLE RESPONSE TO R-MPV TREATMENT AND DEVELOPMENT OF RAPID ALL-IN-ONE GENOTYPING SYSTEM FOR MOLECULAR MARKERS OF PCNSL

    Yamaguchi Junya, Ohka Fumiharu, Lushun Chalise, Motomura Kazuya, Aoki Kosuke, Takeuchi Kazuhito, Nagata Yuichi, Ito Satoshi, Mizutani Nobuhiko, Ohno Masasuke, Suzaki Noriyuki, Takasu Syuntaro, Seki Yukio, Tanahashi Kuniaki, Hirano Masaki, Shimizu Hiroyuki, Kitano Yotaro, Maeda Sachi, Yamazaki Shintaro, Wakabayashi Toshihiko, Kondo Yutaka, Saito Ryuta

    NEURO-ONCOLOGY   Vol. 24   page: 18 - 18   2022.11

  2. CLINICAL AND MOLECULAR FEATURES OF GLIOBLASTOMA, IDH-WILDTYPE ARISING IN THE SETTING OF LI FRAUMENI SYNDROME

    Kibe Yuji, Ohka Fumiharu, Motomura Kazuya, Aoki Kosuke, Maeda Sachi, Yamaguchi Junya, Nishikawa Tomohide, Mizutani Kosuke, Shimizu Hiroki, Hiramatsu Taku, Suzuki Kazuaki, Saito Ryuta

    NEURO-ONCOLOGY   Vol. 24   page: 154 - 154   2022.11

  3. IDENTIFICATION OF A NOVEL THERAPEUTIC TARGET THAT IS SYNTHETICALLY LETHAL WITH MUTANT IDH INHIBITOR IN GLIOMA USING THE CRISPR/CAS9 GENOME EDITING TECHNOLOGY

    Maeda Sachi, Aoki Kosuke, Hinohara Kunihiko, Yamaguchi Junya, Ohka Fumiharu, Motomura Kazuya, Kibe Yuji, Natsume Atsushi, Saito Ryuta

    NEURO-ONCOLOGY   Vol. 24   page: 107 - 107   2022.11

  4. 神経膠腫の術中遺伝子診断を目指した迅速IDH1,H3F3A,BRAF遺伝子変異解析

    大岡史治, 北野詳太郎, 北野詳太郎, 本村和也, 青木恒介, 山口純矢, 平野雅規, 西川知秀, 木部祐士, 前田紗知, 夏目敦至, 齋藤竜太

    日本分子脳神経外科学会プログラム・抄録集   Vol. 21st   2021

     More details

  5. Patient-derived meningioma organoid model demonstrates FOXM1 dependent tumor proliferation

    山崎慎太郎, 大岡史治, 平野雅規, 平野雅規, 白木之浩, 本村和也, 棚橋邦明, 辻内高士, 本村絢子, 青木恒介, 新城恵子, 室伏善照, 北野詳太郎, 前田紗知, 加藤彰, 清水浩之, 山口純矢, アディリジャン アリム, 若林俊彦, 齋藤竜太, 榎本篤, 近藤豊, 夏目敦至

    日本脳腫瘍学会プログラム・抄録集   Vol. 39th   2021

     More details

  6. 高速リアルタイムPCR法による中枢神経系原発悪性リンパ腫におけるMYD88変異の術中迅速解析の有効性の検証

    山口純矢, 大岡史治, 北野詳太郎, 前田紗知, 木部祐士, 西川知秀, 青木恒介, 本村和也, 夏目敦至, 齋藤竜太

    日本分子脳神経外科学会プログラム・抄録集   Vol. 21st   2021

     More details

  7. Rapid gene mutation analysis of glioma using fast real-time PCR method

    前田紗知, 大岡史治, 北野詳太郎, 本村和也, 青木恒介, 平野雅規, 西川知秀, 山口純矢, 山崎慎太郎, 木部祐士, 夏目敦至, 齋藤竜太

    日本脳腫瘍学会プログラム・抄録集   Vol. 39th   2021

     More details

  8. 高速リアルタイムPCR法を用いた迅速IDH1,H3F3A,BRAF遺伝子変異解析

    大岡史治, 北野詳太郎, 本村和也, 清水浩之, 棚橋邦明, 青木恒介, 平野雅規, 山口純矢, 夏目敦至, 齋藤竜太

    Brain Tumor Pathology (Web)   Vol. 38 ( Supplement )   2021

     More details

  9. 覚醒下手術による感情認識に関わる島皮質機能の解明 : 脳とこころの脳神経外科学・認知神経科学の融合型研究—特集 脳とからだ ; 中枢と末梢の相互作用

    本村 和也, 寺澤 悠理, 梅田 聡

    生体の科学   Vol. 72 ( 5 ) page: 461 - 463   2021

     More details

    Language:Japanese   Publisher:金原一郎記念医学医療振興財団 ; 1949-  

    CiNii Books

    Other Link: https://search.jamas.or.jp/link/ui/2022015144

  10. Newly Established Meningioma Organoid Model Elucidated an Important Role of FOXM1 in Meningioma Progression

    山崎慎太郎, 大岡史治, 平野雅規, 本村和也, 棚橋邦明, 竹内和人, 白木之浩, 青木恒介, 北野詳太郎, 清水浩之, 山口純矢, 前田紗知, 榎本篤, 若林俊彦, 夏目敦至

    日本脳腫瘍学会プログラム・抄録集   Vol. 38th   2020

     More details

  11. Outcome of R-MPV treatment for 47 newly diagnosed primary central nervous system lymphoma cases

    大岡史治, 山口純矢, チャリセ ルシュン, チャリセ ルシュン, 本村和也, 竹内和人, 高須俊太郎, 伊藤聡, 大野真佐輔, 棚橋邦明, 青木恒介, 平野雅規, 北野詳太郎, 清水浩之, 山崎慎太郎, 前田紗知, 若林俊彦, 夏目敦至

    日本脳腫瘍学会プログラム・抄録集   Vol. 38th   2020

     More details

  12. 機械学習による神経膠腫尿中バイオマーカーの探索

    北野詳太郎, 青木恒介, 安井隆雄, 大岡史治, 本村和也, 棚橋邦明, 平野雅規, 西川知秀, 清水浩之, 山口純矢, 前田紗知, 山崎慎太郎, 若林俊彦, 馬場嘉信, 夏目敦至

    日本脳腫瘍学会プログラム・抄録集   Vol. 37th   2019

     More details

  13. 機械学習による神経膠腫尿中バイオマーカーの探索

    北野詳太郎, 青木恒介, 安井隆雄, 大岡史治, 本村和也, 棚橋邦明, 平野雅規, 西川知秀, 清水浩之, 山口純矢, 前田紗知, 山崎慎太郎, 若林俊彦, 馬場嘉信, 夏目敦至

    日本脳腫瘍学会プログラム・抄録集   Vol. 37th   2019

     More details

  14. 診断困難な成人diffuse midline glioma,H3 K27M-mutantにおけるddPCRの有用性

    前田紗知, 大岡史治, 平野雅規, 青木恒介, 竹内和人, 本村和也, 棚橋邦明, 加藤彰, 北野詳太郎, 西川知秀, 清水浩之, 山口純矢, 山崎慎太郎, 若林俊彦, 夏目敦至

    日本分子脳神経外科学会プログラム・抄録集   Vol. 20th   2019

     More details

  15. Does ATRX immunohistochemistry deserve a surrogate of 1p/19q codel in grade II, III gliomas? Reviewed

    Yamamichi Akane, Ohka Fumiharu, Aoki Kosuke, Suzuki Hiromichi, Hirano Masaki, Motomura Kazuya, Wakabayashi Toshihiko, Kato Yukinari, Natsume Atsushi

    CANCER SCIENCE   Vol. 109   page: 926   2018.1

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)  

  16. IS ATRX IMMUNOCHEMISTRY USEFUL AS A SUBSTITUTE FOR ANALYSIS OF 1p/19q CODELETION IN GRADES II, III GLIOMAS?

    Akane Yamamichi, Fumiharu Ohka, Kosuke Aoki, Hiromichi Suzuki, Masaki Hirano, Kazuya Motomura, Toshihiko Wakabayashi, Yukinari Kato, Atsushi Natsume

    NEURO-ONCOLOGY   Vol. 19   page: 180 - 180   2017.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:OXFORD UNIV PRESS INC  

    Web of Science

  17. Remote ischemic preconditioning protects human neural stem cells from oxidative stress International journal

    Ayako Motomura, Mikiko Shimizu, Akira Kato, Kazuya Motomura, Akane Yamamichi, Hiroko Koyama, Fumiharu Ohka, Tomohide Nishikawa, Yusuke Nishimura, Masahito Hara, Tetsuya Fukuda, Yasuhiko Bando, Toshihide Nishimura, Toshihiko Wakabayashi, Atsushi Natsume

    APOPTOSIS   Vol. 22 ( 11 ) page: 1353 - 1361   2017.11

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:SPRINGER  

    In previous clinical trials, we showed that remote ischemic preconditioning (rIPC) reduced myocardial damage in children undergoing treatment for congenital heart defects and postoperative renal failure in patients undergoing abdominal aortic aneurysm surgery. In rabbit experiments, pre-treatment with plasma and plasma dialysate (obtained using 15-kDa cut-off dialysis membrane) from donor rabbits subjected to rIPC similarly protected against cardiac infarction. However, the protective substances containing in rIPC plasma have been unknown. In the present study, we showed that rIPC plasma exerted anti-apoptotic and anti-oxidative effects on human neural stem cells under oxygen glucose deprivation (OGD) that mimics brain ischemia. Additionally, we applied the sample to the liquid chromatography integrated with mass spectrometry to identify candidate key molecules in the rIPC plasma and determine its role in protecting neural stem cells from OGD-induced cell death. Thioredoxin increased significantly after rIPC compared to pre-IPC. Pretreatment with thioredoxin, the antioxidant protein, markedly protected human neural stem cells from OGD-induced cell death. The effect of thioredoxin on brain ischemia in animals should be further evaluated. However, the present study first evaluated the effect of rIPC in the ischemic cellular model.

    DOI: 10.1007/s10495-017-1425-8

    Web of Science

    PubMed

  18. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study International journal

    Lushun Chalise, Kazuya Motomura, Fumiharu Ohka, Masaki Hirano, Masahito Hara, Yusuke Nishimura, Atsushi Natsume, Toshihiko Wakabayashi

    ANTICANCER RESEARCH   Vol. 37 ( 9 ) page: 5215 - 5223   2017.9

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:INT INST ANTICANCER RESEARCH  

    Background/Aim: In the current study, we aimed to compare DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy with high-dose methotrexate (HD-MTX) monotherapy plus whole-brain radiation therapy (WBRT) for newly-diagnosed primary central nervous system lymphoma (PCNSL), in terms of their efficacies and tolerability. Patients and Methods: A total of 21 consecutive patients with PCNSL were treated with DeVIC therapy and WBRT, between 2002 and 2010. From 2010 to 2014, 14 consecutive patients with PCNSL were treated with HD-MTX followed by WBRT. Results: Overall response rates of complete and partial response for initial chemotherapy were significantly better with DeVIC therapy (95.2%) than with HD-MTX monotherapy (50%). Furthermore, one-year and two-year progression-free survival (PFS) rates were better in the DeVIC cohort than in the HD-MTX cohort. DeVIC therapy yielded higher early response rates, longer PFS, and manageable adverse events, and may be potentially better for the treatment of cases that are refractory to MTX-based therapy. Conclusion: Our retrospective clinical study revealed that DeVIC therapy is comparable with that of HD-MTX monotherapy plus WBRT, for newly diagnosed PCNSL.

    DOI: 10.21873/anticanres.11945

    Web of Science

    PubMed

  19. グレードII、IIIグリオーマ分子診断におけるATRX免疫組織染色の1p/19q共欠失のサロゲートマーカーとしての有用性は真実か?

    山道 茜, 大岡 史治, 青木 恒介, 鈴木 啓道, 平野 雅規, 本村 和也, 若林 俊彦, 加藤 幸成, 夏目 敦至

    日本癌学会総会記事   Vol. 76回   page: E - 3048   2017.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:日本癌学会  

  20. グレードII、IIIグリオーマにおいてATRX免疫組織染色は1p/19q共欠失のサロゲートになりうるのか?

    山道 茜, 大岡 史治, 青木 恒介, 平野 雅規, Chalise Lushun, 棚橋 邦明, 本村 和也, 若林 俊彦, 加藤 幸成, 夏目 敦至

    Brain Tumor Pathology   Vol. 34 ( Suppl. ) page: 112 - 112   2017.5

     More details

    Language:Japanese   Publishing type:Research paper, summary (international conference)   Publisher:日本脳腫瘍病理学会  

  21. A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma

    Fumiharu Ohka, Akane Yamamichi, Michihiro Kurimoto, Kazuya Motomura, Kuniaki Tanahashi, Hiromichi Suzuki, Kosuke Aoki, Shoichi Deguchi, Lushun Chalise, Masaki Hirano, Akira Kato, Yusuke Nishimura, Masahito Hara, Yukinari Kato, Toshihiko Wakabayashi, Atsushi Natsume

    BRAIN TUMOR PATHOLOGY   Vol. 34 ( 2 ) page: 91 - 97   2017.4

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:SPRINGER JAPAN KK  

    IDH1 gene mutation has been demonstrated to be an oncogenic driver in a majority of lower-grade gliomas (LGGs). In contrast to other central nervous neoplasms and normal brain tissue without IDH1 mutation, almost 80% of LGGs exhibit IDH1 mutation. Therefore, expeditious detection of IDH1 mutation is useful, not only for intraoperative diagnosis of these gliomas but also for determination of the border between the tumor and normal brain tissue. In this study, we established a rapid genotyping assay with a simple DNA extraction method, involving only incubation of the tumor specimen with Tris-EDTA buffer, which can be easily performed in an operating room. In all 11 tested cases, we could identify the IDH1 status within 90-100 min intraoperatively. In a case of anaplastic astrocytoma, IDH-mutant, we could detect the tumor border by IDH1 profiling. In addition, with this assay, we could detect IDH1 mutation using cell-free tumor DNA derived from cerebrospinal fluid in a case of glioblastoma, IDH-mutant. Considering that clinical trials of mutated IDH1 inhibitors are ongoing, less-invasive intraoperative IDH1 gene profiling might be useful for decision making of the overall treatment strategy of LGGs. Our assay might be a useful tool for precision medicine and surgery of IDH1-mutant gliomas.

    DOI: 10.1007/s10014-017-0281-0

    Web of Science

    PubMed

  22. Efficacy of the transtemporal approach with awake brain mapping to reach the dominant posteromedial temporal lesions International journal

    Kentaro Iijima, Kazuya Motomura, Lushun Chalise, Masaki Hirano, Atsushi Natsume, Toshihiko Wakabayashi

    ACTA NEUROCHIRURGICA   Vol. 159 ( 1 ) page: 177 - 184   2017.1

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:SPRINGER WIEN  

    Background Surgeries for lesions in the dominant hippocampal and parahippocampal gyrus involving the posteromedial temporal regions are challenging to perform because they are located close to Wernicke's area; white matter fibers related with language; the optic radiations; and critical neurovascular structures. We performed a transtemporal approach with awake functional mapping for lesions affecting the dominant posteromedial temporal regions. The aim of this study was to assess the feasibility, safety, and efficacy of awake craniotomy for these lesions.
    Methods We retrospectively reviewed four consecutive patients with tumors or cavernous angiomas located in the left hippocampal and parahippocampal gyrus, which further extended to the posteromedial temporal regions, who underwent awake surgery between December 2014 and January 2016.
    Results Four patients with lesions associated with the left hippocampal and parahippocampal gyrus, including the posteromedial temporal area, who underwent awake surgery were registered in the study. In all four patients, cortical and subcortical eloquent areas were identified via direct electrical stimulation. This allowed determination of the optimal surgical route to the angioma or tumor, even in the language-dominant hippocampal and parahippocampal gyrus. In particular, this approach enabled access to the upper part of posteromedial temporal lesions, while protecting the subcortical language-related fibers, such as the superior longitudinal fasciculus.
    Conclusions This study revealed that awake brain mapping can enable the safe resection of dominant posteromedial temporal lesions, while protecting cortical and subcortical eloquent areas. Furthermore, our experience with four patients demonstrates the feasibility, safety, and efficacy of awake surgery for these lesions.

    DOI: 10.1007/s00701-016-3035-6

    Web of Science

    PubMed

▼display all

Presentations 128

  1. The efficacy of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblatoma: Multicenter study. International conference

    Motomura K, Natsume A, Fujii M, Ito M, Namba H, Abe T, Nakasu Y, Watanabe R, Wakai K, Wakabayashi T

    2010 ASCO Annual' 10 meeting  2010.6.4 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  2. WHO grade II diffuse astrocytomaに おけるPDGFRA / MET gainの腫瘍内不均一性

    本村和也、夏目敦至、若林俊彦、Hiroko Ohgaki

    第31回日本脳腫瘍病理学会  2013.5.25 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  3. Diffuse astrocyotomaにおける新たなバイオマーカーの発見~IARC, WHOからの最新知見~

    本村和也, Daniela Pierscianek, Hiroko Ohgaki

    第30回日本脳腫瘍学会学術学会  2012.11.26 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Venue:広島   Country:Japan  

  4. 代謝関連遺伝子IDH1変異を中心とした免疫組織染色解析に基づく初発膠芽腫のサブタイプ診断と個別化医療への展望

    本村和也、夏目敦至、渡邊 麗子、伊藤伊知郎、加藤幸成、百田洋之、西川亮、三島一彦、中洲庸子、阿部竜也、難波宏樹、中里洋一、田代広、竹内一郎、若林俊彦

    第70回日本神経外科学会学術集会  2011.10.14 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:横浜   Country:Japan  

  5. 膠芽腫における組織染色でのmIDH1など16マーカー発現とゲノム・エピゲノム解析によるsubtype分類と予後検討

    本村和也、夏目敦至、渡邊 麗子、百田洋之、藤井正純、西川亮、三島一彦、中洲庸子、阿部竜也、難波宏樹、加藤幸成、中里洋一、若林俊彦

    第29回日本脳腫瘍病理学会  2011.5.20 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  6. 初発膠芽腫に対する免疫組織染色を用いたGBM subtype analysisとその予後検討

    本村和也、夏目敦至、渡邊 麗子、百田洋之、藤井正純、西川亮、三島一彦、中洲庸子、阿部竜也、難波宏樹、中里洋一、若林俊彦

    第28回日本脳腫瘍学会学術学会  2010.11.29 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:軽井沢   Country:Japan  

  7. Intra-tumoral heterogeneity of PDGFRA / MET gain in WHO grade II diffuse astrocytomas International conference

    Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y,Tanaka Y, Nonoguchi N, Pierscianek D, Kim YH, Mariani L, Vital A, Perry A, Ohgaki H

    AACR Annual Meeting 2013  2013.4.6 

     More details

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  8. 頭頂葉・神経膠腫における覚醒下機能マッピング・モニタリング

    本村和也、藤井正純、前澤聡、倉光俊一郎、杉浦淳子、飛永真希、原大介、松井泰行、堤ちあき、水口貴詞、二村 美也子、下田伊津子、若林俊彦

    第18回日本脳腫瘍の外科学会  2013.9.19 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  9. 脳腫瘍手術における術中運動神経モニタリング

    本村和也

    第3回奈良術中神経モニター講習会  2013.8.17 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  10. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, carboplatin based chemotherapy followed by radiotherapy International conference

    Kazuya Motomura, Atsushi Natsume and Toshihiko Wakabayashi

    15th European Congress of Neurosurgery (EANS 2014)  2014.10.12 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Prague   Country:Czech Republic  

  11. Clinical outcome of surgery, carboplatin based chemotherapy followed by radiotherapy in patients with primary intracranial germ cell tumors International conference

    Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi

    15th Interim Meeting of the World Federation of Neurosurgical Societies   2015.9.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Italy  

  12. 高次脳機能温存を目指した覚醒下手術 Invited

    本村和也

    第40回日本脳神経外科コングレス総会  2020.8.1 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:金沢   Country:Japan  

  13. 覚醒下脳機能マッピングに基づく島皮質前部と感情認識に関わる脳機能ネットワークの解明

    本村和也、寺澤悠理、夏目敦至、飯島健太郎、Lushun Chalise、杉浦淳子、山本裕泰、小山恭平、若林俊彦、梅田聡

    第17回日本Awake Surgery学会  2019.10.12 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:大阪   Country:Japan  

  14. 覚醒下手術による感情認識に関わる脳機能ネットワークの解明-脳神経外科学・認知神経科学の融合型研究-  

    本村和也、梅田聡、寺澤悠理、夏目敦至、若林俊彦

    日本脳神経外科学会第78回学術総会  2019.10.9 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:大阪   Country:Japan  

  15. 覚醒下脳機能マッピングによる 前頭葉lower-grade gliomaの神経認知機能温存と長期無増悪生存成績について 

    村和也、Lushun Chalise、西川知秀、山口純矢、清水浩之、若林俊彦、夏目敦至

    第24回日本脳腫瘍の外科学会  2019.9.13 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:浜松   Country:Japan  

  16. Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas using intraoperative awake functional mapping  International conference

    Kazuya Motomura

    2019.9.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:北京   Country:China  

  17. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, carboplatin based chemotherapy followed by radiotherapy International conference

    Kazuya Motomura

    Neurosurgical Society Of Australasia Annual Scientific Meeting 2019  2019.8.21 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Melbourne   Country:Australia  

  18. Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping International conference

    Kazuya Motomura

    Neurosurgical Society Of Australasia Annual Scientific Meeting 2019  2019.8.21 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Melbourne   Country:Australia  

  19. 言語野に関わる新しい神経線維について~覚醒下脳機能マッピングからの知見~ Invited

    本村和也

    第14回愛知県言語聴覚士総会  2019.6.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (keynote)  

    Venue:名古屋   Country:Japan  

  20. Anterior insular cortex stimulation and its effects on emotion recognition International conference

    Kazuya Motomura, Yuri Terasawa, Atsushi Natsume, Toshihiko Wakabayashi, Satoshi Umeda

    Organization for Human Brain Mapping (OHBM) 2019 Annual Meeting  2019.6.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Rome   Country:Italy  

  21. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, carboplatin based chemotherapy followed by radiotherapy International conference

    Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi

    American Association of Neurological Surgeons (AANS) Annual Scientific Meeting  2019.4.13 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:San Diego   Country:United States  

  22. One theater 0.4T術中MRIにおける 医療安全管理について Invited

    本村和也、夏目敦至、若林俊彦

    第20回日本術中画像情報学会  2020.12.12 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:東京   Country:Japan  

  23. 頭蓋内胚細胞性腫瘍における長期治療成績および認知神経機能成績について

    本村和也、清水浩之、大岡史治、青木恒介、棚橋邦明、平野雅規、Lushun Chalise、西川知秀、山口純矢、吉田純、夏目敦至、若林俊彦

    第38回日本脳腫瘍学会学術集会  2020.12.1 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:広島  

  24. 脳腫瘍関連てんかんの治療に パラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    日本脳神経外科学会第79回学術総会  2020.10.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:岡山   Country:Japan  

  25. 覚醒下脳機能マッピングによるlower-grade gliomaに対する手術戦略

    本村和也、清水浩之、山口純矢、Lushun Chalise、西川知秀、若林俊彦、夏目敦至

    日本脳神経外科学会第79回学術総会  2020.10.16 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:岡山   Country:Japan  

  26. 高精度ナビゲーション下反復経頭蓋磁気刺激法による 覚醒下手術前・言語機能評価の有用性

    本村和也、竹内裕喜、野嶌一平、青木恒介、チャリセルシュン、飯島健太郎、若林俊彦、夏目敦至

    第18回日本Awake Surgery学会  2020.10.3 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  27. 覚醒下手術による感情認識に関わる島皮質機能の解明-脳神経外科学・認知神経科学の融合型研究-

    本村和也、寺澤悠理、夏目敦至、飯島健太郎、チャリセ ルシュン、杉浦淳子、山本裕泰、小山恭平、若林俊彦、梅田聡 

    第18回日本Awake Surgery学会  2020.10.3 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  28. 脳腫瘍手術における止血手技について~止血剤の選び方と使い方~ Invited

    本村和也

    第25回日本脳腫瘍の外科学会  2020.9.12 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  29. Lower-grade gliomaに対する 覚醒下脳機能マッピングの意義について

    本村和也、清水浩之、山口純矢、Lushun Chalise、西川知秀、若林俊彦、夏目敦至

    第25回日本脳腫瘍の外科学会  2020.9.1 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:名古屋   Country:Japan  

  30. 覚醒下脳機能マッピングによる 前頭葉lower-grade gliomaの神経認知機能温存について

    本村和也、Lushun Chalise、西川知秀、山口純矢、清水浩之、若林俊彦、夏目敦至

    第17回日本Awake Surgery学会  2019.10.12 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  31. 次世代医療機器ナビゲーション下経頭蓋磁気刺激(nTMS)システムによる新たな脳機能マッピング法の確立

    本村和也、竹内裕喜、夏目敦至、藤井正純、前澤聡、倉光俊一郎、若林俊彦

    第31回日本脳腫瘍学会学術集会  2013.12.8 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Venue:宮崎   Country:Japan  

  32. ナビゲーション下経頭蓋磁気刺激法(nTMS)と覚醒下機能マッピング・モニタリングの融合—functional MRIとnTMSの比較検討

    本村和也、竹内裕喜、藤井正純、前澤聡、倉光俊一郎、夏目敦至、Hugues Duffau、若林俊彦

    日本脳神経外科学会第72回学術総会  2013.10.18 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  33. 覚醒下機能マッピング・モニタリングを駆使した左頭頂葉腫瘍への挑戦

    本村和也、藤井正純、前澤聡、倉光俊一郎、杉浦淳子、飛永真希、原大介、松井泰行、二村 美也子、下田伊津子、夏目敦至、若林俊彦

    第37回日本神経心理学会  2013.9.13 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌   Country:Japan  

  34. 覚醒下手術・皮質下マッピングによる書字・音読に関わる白質線維の同定

    本村和也、藤井正純、前澤聡、倉光俊一郎、杉浦淳子、飛永真希、原大介、松井泰行、二村 美也子、下田伊津子、夏目敦至、若林俊彦

    第11回日本Awake Surgery研究会  2013.8.24 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  35. PDGFRA Gain in Low-Grade Diffuse Gliomas International conference

    Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y,Tanaka Y, Nonoguchi N, Pierscianek D, Kim YH, Mariani L, Vital A, Perry A, Ohgaki H

    IARC Scientific Council Forty-nineth session  2013.2.1 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Lyon   Country:France  

  36. 頭蓋内胚細胞腫瘍に対する 治療戦略と長期治療成績

    本村和也 若林俊彦

    第32回日本脳腫瘍学会学術集会  2014.11.30 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  37. グリオーマ治療における覚醒下手術 intraoperative MRIを駆使した外科的摘出術の意義

    本村和也 藤井正純 前澤聡 山本高士 夏目敦至 若林俊彦

    日本脳神経外科学会第73回学術総会  2014.10.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  38. 覚醒下手術、intraoperative MRIを 統合させたgrade II/IIIグリオーマに 対する手術戦略 

    本村和也 藤井正純 前澤聡 山本高士 夏目敦至 若林俊彦

    第19回日本脳腫瘍の外科学会  2014.9.12 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  39. 覚醒下機能マッピングによる、書字・音読に関わる白質線維・dorsal inferior frontooccipital fasciculus (IFOF) の同定

    本村和也 藤井正純 前澤聡 倉光俊一郎 夏目敦至 若林俊彦

    第12回日本Awake Surgery研究会  2014.9.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  40. 優位半球の海馬・海馬傍回病変に対する 覚醒下機能マッピングの有用性

    本村和也 飯島健太郎 夏目敦至 若林俊彦

    第33回日本脳腫瘍学会学術集会  2015.12.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:京都   Country:Japan  

  41. 術中脳機能マッピングとしての次世代覚醒下手術の確立にむけて

    本村和也 夏目敦至 飯島健太郎 山本高士 若林俊彦

    日本脳神経外科学会第74回学術総会  2015.10.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌   Country:Japan  

  42. Lower grade gliomaの悪性転化に 関わる遺伝子解析 Invited

    本村和也、鈴木啓道、青木恒介、夏目敦至、Hiroko Ohgaki、若林俊彦

    第4回Neuro-Oncology West  2015.10.3 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:大阪   Country:Japan  

  43. ナビゲーション使用のA to Z ~プランニングから術中ナビゲーションまで~ Invited

    本村和也

    第20回日本脳腫瘍の外科学会  2015.9.25 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  44. グリオーマ治療に対する ギリアデルの治療成績 Invited

    本村和也

    第20回日本脳腫瘍の外科学会  2015.9.25 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  45. 言語優位半球の海馬海綿状血管腫に 対する覚醒下機能マッピングの有用性

    本村和也 飯島健太郎 夏目敦至 若林俊彦

    第13回Awake Surgery学会  2015.9.24 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:名古屋   Country:Japan  

  46. 覚醒下手術と術中MRIの融合による、言語・運動関連領域グリオーマに対する手術戦略 ~脳機能温存と最大限の腫瘍摘出を目指して~

    本村和也、夏目敦至、飯島健太郎、Lushun Chalise、平野雅規、若林俊彦

    第34回日本脳腫瘍学会学術集会  2016.12.4 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Venue:甲府   Country:Japan  

  47. 脳腫瘍手術・術前脳機能評価のための 高精度ナビゲーション下反復経頭蓋磁気刺激法の有用性

    本村和也、竹内裕喜、夏目敦至、若林俊彦

    日本脳神経外科学会第75回学術総会  2016.9.30 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡   Country:Japan  

  48. 術中MRIと覚醒下手術の融合による eloquent area関連グリオーマに対する手術戦略  ~脳機能温存と最大限の腫瘍摘出を目指して~

    本村和也、夏目敦至、飯島健太郎、Lushun Chalise、平野雅規、若林俊彦

    第21回日本脳腫瘍の外科学会  2016.9.9 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  49. 前部帯状回を含むグリオーマ摘出における 覚醒下手術前後での神経機能の変化について

    本村和也、夏目敦至、飯島健太郎、Lushun Chalise、平野雅規、若林俊彦

    第14回Awake surgery学会  2016.9.8 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  50. Image-guided deep seated glioma surgery Invited International conference

    Kazuya Motomura, Toshihiko Wakabayashi

    7th International Congress of World Federation of Skull Base Societies (World Skull Base 2016)  2016.6.16 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  51. Long-term survival with multimodal therapy; surgery, carboplatin based chemotherapy followed by radiotherapy in patients with primary intracranial germ cell tumors Invited International conference

    Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi

    21st International Conference on Brain Tumor Research and Therapy (ICBTRT)  2016.4.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  52. ガンマナイフ治療後外科的手術を 要した聴神経腫瘍についての検討

    本村和也 夏目敦至 若林俊彦

    第25回日本聴神経腫瘍研究会  2016.6.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  53. グリオーマ手術における supra-total removalを可能とする 覚醒下脳機能マッピングの意義ついて

    本村和也、Lushun Chalise、西川知秀、夏目敦至、若林俊彦

    第35回日本脳腫瘍学会学術集会  2017.11.27 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:香川   Country:Japan  

  54. 脳腫瘍に対する手術戦略~手術器具の選び方と使い方~ Invited

    本村和也、若林俊彦

    日本脳神経外科学会第76回学術総会  2017.10.13 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  55. グレード2神経膠腫に対する治療方針:今後の展望

    本村和也

    日本脳神経外科学会第76回学術総会  2017.10.13 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋   Country:Japan  

  56. Eloquent area関連脳腫瘍に対する 術中MRIと覚醒下手術融合による 画像誘導手術について Invited

    本村和也、若林俊彦

    日本脳神経外科学会第76回学術総会  2017.10.12 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋   Country:Japan  

  57. 覚醒下脳機能マッピングにより 言語、運動、高次脳機能部位を摘出限界とした グリオーマに対するsupra-total removalについて

    本村和也、Lushun Chalise、夏目敦至、若林俊彦

    第15回日本Awake Surgery学会  2017.9.30 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  58. 覚醒下脳機能マッピングによるSupratotal removalを目指した グリオーマ手術への挑戦

    本村和也、Lushun Chalise、平野雅規、夏目敦至、若林俊彦

    第22回日本脳腫瘍の外科学会  2017.9.9 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:鹿児島   Country:Japan  

  59. 医療機器と複合材の融合の 展望について Invited

    本村和也

    第3回複合材料を用いたマテリアルデザインによる高機能化部品・構造開発研究会  2018.1.24 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  60. 術中MRI・ナビゲーションを用いた画像誘導手術支援によるDeep seated gliomaへの挑戦 Invited

    本村和也、Lushun Chalise、平野雅規、西川知秀、夏目敦至、若林俊彦

    第41回日本脳神経CI学会総会  2018.3.2 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:新潟   Country:Japan  

  61. 次世代グリオーマ手術戦略の現状と近未来 -脳機能温存を重要視した最大限の摘出-

    本村和也、Lushun Chalise、西川知秀、山口純矢、夏目敦至、若林俊彦

    第36回日本脳腫瘍学会学術集会  2018.12.2 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:小田原   Country:Japan  

  62. 覚醒下脳機能マッピングによる前頭葉GII/III神経膠腫に対する手術戦略 

    本村和也、Lushun Chalise、西川知秀、山口純矢、夏目敦至、若林俊彦

    日本脳神経外科学会第77回学術総会  2018.10.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:仙台   Country:Japan  

  63. Anterior insular cortex stimulation and its effects on emotion recognition

    Kazuya Motomura, Satoshi Umeda, Yuri Terasawa, Toshihiko Wakabayashi

    2018.9.29 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  64. 覚醒下脳機能マッピングによる 前頭葉lower grade gliomaに対する手術戦略

    本村和也、Lushun Chalise、西川知秀、山口純矢、夏目敦至、若林俊彦

    第23回日本脳腫瘍の外科学会  2018.9.14 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Venue:和歌山   Country:Japan  

  65. 前頭葉lower grade gliomaに対する 覚醒下脳機能マッピングを用いた手術戦略

    本村和也、Lushun Chalise、西川知秀、山口純矢、夏目敦至、若林俊彦

    第16回日本Awake Surgery学会  2018.9.8 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  66. Supratotal resection of diffuse frontal lower-grade gliomas with awake brain mapping while preserving motor, language, and neurocognitive functions International conference

    Neurosurgical Society Of Australasia Annual Scientific Meeting 2018   2018.8.29 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Gold Coast   Country:Australia  

  67. Insular function with emotional experience and interoceptive awareness using the awake surgery International conference

    Kazuya Motomura, Yuri Terasawa, Atsushi Natsume, Toshihiko Wakabayashi, Satoshi Umeda

    2018 OHBM Annual Meeting  2018.6.17 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Singapore  

  68. 脳機能統合的イメージングとしての反復経頭蓋磁気刺激法による言語マッピングの有用性

    本村和也、竹内裕喜、若林俊彦、夏目敦至

    第37回日本脳腫瘍学会学術集会  2019.12.1 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:石川   Country:Japan  

  69. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, carboplatin-based chemotherapy followed by radiotherapy International conference

    Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi

    International Society of Pediatric Oncology (SIOP)2019  2019.10.23 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Lyon   Country:France  

  70. 免疫組織染色解析に基づく新たな初発膠芽腫のサブタイプ分類と層別化治療への展望

    本村和也, 夏目敦至, 渡邊麗子, 伊藤以知郎, 加藤幸成, 百田洋之, 西川亮, 三島一彦, 中洲庸子, 阿部竜也, 難波宏樹, 中里洋一, :田代弘, 竹内一郎, 森努, 若林俊彦

    第30回日本脳腫瘍学会学術集会  2012.11.26 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    Venue:広島   Country:Japan  

  71. 覚醒下手術 術中痙攣発作コントロールにおけるレベチラセタム・ペランパネル併用療法の有効性について

    本村和也、Lushun Chalise、清水浩之、山口純矢、 西川知秀、夏目敦至、若林俊彦、齋藤竜太

    第19回日本Awake Surgery学会  2021.6.20 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌   Country:Japan  

  72. Lower-grade gliomaに対する覚醒下脳機能マッピングによる腫瘍摘出の意義について

    本村和也、Lushun Chalise、清水浩之、山口純矢、 西川知秀、夏目敦至、若林俊彦、齋藤竜太

    第19回日本Awake Surgery学会  2021.6.20 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌   Country:Japan  

  73. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか?~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    第41回脳神経外科コングレス総会  2021.5.14 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:横浜   Country:Japan  

  74. Multi-modality imagingの手術支援システムを用いた脳腫瘍手術について

    本村和也

    MERRO第1回次世代若手医・理・工連携研究会  2015.1.17 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:蒲郡   Country:Japan  

  75. 島回転移性脳腫瘍に対する手術戦略

    本村和也

    脳転移ワークショップ  2015.2.14 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:豊田   Country:Japan  

  76. 覚醒下開頭術の現状と今後の展望

    本村和也

    第3回名大京大フレンドシップ  2013.3.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  77. 当施設のおけるテモダール点滴静注の使用経験

    本村和也

    東海脳腫瘍セミナー  2010.7.30 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  78. 当施設のおける静注テモゾロミド療法の臨床経験 Invited

    本村和也

    東海脳腫瘍セミナー  2011.2.19 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  79. Low-grade diffuse gliomasに対する覚醒下開頭術

    本村和也

    東海脳腫瘍セミナー  2013.1.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Country:Japan  

  80. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍Webカンファレンスセミナー  2020.9.29 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋   Country:Japan  

  81. 覚醒下手術による高次脳機能温存を目指した次世代グリオーマ手術 Invited

    本村和也、若林俊彦、夏目敦至

    第11回東海脳腫瘍手術手技研究会  2019.6.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:名古屋   Country:Japan  

  82. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    Premium Digital Conference  2020.11.24 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋   Country:Japan  

  83. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍治療戦略セミナー  2020.11.2 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Venue:名古屋   Country:Japan  

  84. 覚醒下手術の最新の現状~てんかんの管理も含めて~ Invited

    本村和也

    尾北脳神経外科懇話会  2019.11.29 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  85. 成人膠芽腫治療ガイドライン~ギリアデル使用の位置づけと当院の使用経験~ Invited

    本村和也

    Gliadel Meet the Expert   2014.8.1 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  86. 言語・運動機能領域に関わる 浸潤性脳腫瘍に対する手術戦略 Invited

    本村和也

    第8回 岐阜大学動物病院 中部小動物神経病検討会  2016.12.22 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  87. 脳外科手術の最前線 Invited

    本村和也

    大同病院第2回病院祭・市民公開講座  2016.11.13 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  88. Eloquent areaに関わるグリオーマに 対する手術戦略 Invited

    本村和也

    第2回三河脳神経外科セミナー  2016.7.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:安城   Country:Japan  

  89. 覚醒下開頭手術における 脳神経外科医と麻酔科医との チーム医療について Invited

    本村和也

    名古屋周術期全身管理セミナー2017  2017.7.8 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  90. 覚醒下手術によるグリオーマに対する手術戦略~脳機能温存と最大限の腫瘍摘出を目指して~ Invited

    本村和也

    第25回静岡脳神経外科ビデオシンポジウム  2018.6.23 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:静岡   Country:Japan  

  91. 日立製ナビゲーション臨床使用経験について Invited

    本村和也

    日立術中MRIユーザーミーティング  2019.1.23 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:東京   Country:Japan  

  92. 安全な脳腫瘍手術について Invited

    本村和也

    第1回安全な脳腫瘍手術を考える会  2019.10.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:大阪   Country:Japan  

  93. グリオーマに対する手術戦略 Invited

    本村和也

    CUSA Clarity training Seminar  2019.12.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:成田   Country:Japan  

  94. Eloquent areaに関わるグリオーマに対する手術戦略 Invited

    本村和也

    第4回武蔵脳神経外科手術手技研究会  2015.1.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:東京   Country:Japan  

  95. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    十勝脳腫瘍治療セミナー  2021.5.20 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:十勝   Country:Japan  

  96. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍Webカンファレンスセミナー  2021.3.31 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  97. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    グルタメートカンファランス  2021.2.27 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:東京   Country:Japan  

  98. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか? ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍Webカンファレンスセミナー  2021.2.2 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:名古屋   Country:Japan  

  99. 脳腫瘍関連てんかんの治療にパラダイムシフトは起こり得るか?~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍てんかんを考える会in秋田  2021.1.13 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    Venue:秋田   Country:Japan  

  100. 言語運動関連領域に関わるグリオーマに対する手術戦略

    本村和也

    第3回TOMぶり街道カンファランス  2015.3.14 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:高山   Country:Japan  

  101. Eloquent areaのグリオーマに対する手術戦略

    本村和也

    第5回名大京大フレンドシップ   2015.2.17 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:浜松   Country:Japan  

  102. 高次脳機能温存を目指した覚醒下手術 Invited

    本村和也, 大岡史治, 齋藤竜太

    第31回脳神経外科手術と機器学会  2022.4.16 

     More details

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

  103. 高次脳機能温存を目指した 前頭葉グリオーマに対する覚醒下手術

    本村和也, 大岡史治, 齋藤竜太

    第20回日本Awake Surgery学会  2022.7.16 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

  104. Clinical and molecular features of IDH wild-type diffuse astrocytomas presenting with focal diffuse brain infiltration: A single-institution case series

    Kazuya Motomura, Yuji Kibe, Fumiharu Ohka, Kosuke Aoki Hiroyuki, Shimizu Junya, Yamaguchi, Tomohide Nishikawa, Ryuta Saito

    2022.5.28 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

  105. Hybrid visualization systemを用いた 覚醒下手術における新たな試み ~顕微鏡手術から外視鏡手術への可能性~ Invited

    本村和也, 齋藤竜太

    第26回日本脳腫瘍の外科学会イブニングセミナー  2021.9.9 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  106. IDH1変異型低悪性度神経膠腫に対する 覚醒下脳機能マッピングによる 腫瘍摘出の意義について

    本村和也, Lushun Chalise, 大岡史治, 青木恒介, 西川知秀, 山口純矢, 清水浩之, 木部祐士, 齋藤竜太

    日本脳神経外科学会 第80回学術総会  2021.11.27 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

  107. Lower-grade gliomaに対する 覚醒下脳機能マッピングによる腫瘍摘出の意義について

    本村和也, Lushun Chlise, 大岡史治, 青木恒介, 西川知秀, 山口純矢, 清水浩之, 木部祐士, 夏目敦至, 若林俊彦, 齋藤竜太

    第39回日本脳腫瘍学会  2021.12.5 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  108. WHO2021脳腫瘍分類に基づく 島回神経膠腫の治療成績と予後因子についての検討

    本村和也, 大岡史治, 山口純矢, 西川知秀, 木部祐士, 清水大輝, 齋藤竜太

    第40回日本脳腫瘍学会学術集会  2022.12.4 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  109. グレードII、III神経膠腫に対する 覚醒下脳機能マッピングによる腫瘍摘出の意義について

    本村和也, Lushun Chalise, 大岡史治, 青木恒介, 西川知秀, 山口純矢, 清水浩之, 木部祐士, 夏目敦至, 若林俊彦, 齋藤竜太

    第26回日本脳腫瘍の外科学会  2021.9.9 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

  110. 悪性脳腫瘍手術における止血手技について~止血剤の選び方と使い方~ Invited

    本村 和也, 齋藤, 竜太

    日本脳神経外科学会第80回学術総会 ランチョンセミナー  2021.10.28 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  111. 新型超音波手術機器を用いたグリオーマ手術 ~手術テクニックおよび硬膜閉創のピットフォール~ Invited

    本村 和也, 齋藤, 竜太

    第42回日本脳神経外科コングレス総会 ランチョンセミナー  2022.5.15 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  112. 脳機能ネットワーク解明を目指した 覚醒下脳機能マッピングに基づくIn-house独自研究 Invited

    本村和也, 大岡史治, 齋藤竜太

    日本脳神経外科学会第81回学術総会  2022.9.29 

     More details

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

  113. 脳腫瘍手術におけるフロアブル止血剤の有用性 ~フロシールの使用経験~ Invited

    本村和也, 齋藤竜太

    日本脳神経外科学会第81回学術総会 ランチョンセミナー  2022.9.29 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  114. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也, 齋藤竜太

    第81回日本脳神経外科学会近畿支部学術集会 ランチョンセミナー  2022.4.2 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  115. 覚醒下手術中痙攣発作コントロールにおける レベチラセタム・ペランパネル併用療法の 有効性について Invited

    本村和也, 齋藤竜太

    第39回日本神経治療学会  2021.10.30 

     More details

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

  116. 覚醒下脳機能マッピングによる 島回神経膠腫の治療成績と予後因子についての検討

    本村和也, 鈴木一秋, 大岡史治, 山口純矢, 西川知秀, 木部祐士, 水谷高輔, 清水大輝, 平松拓, 齋藤竜太

    日本脳神経外科学会第81回学術総会  2022.9.29 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  117. 覚醒下脳機能マッピングによるSupratotal removalを 目指したLower-grade gliomaの手術戦略 ~最大限の腫瘍切除と脳機能温存の両立~

    本村和也, 大岡史治, 西川知秀, 山口純矢, 木部祐士, 清水大輝, 鈴木一秋, 齋藤竜太

    第27回日本脳腫瘍の外科学会  2022.10.14 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

  118. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    Neurosurgery Update Seminar  2021.8.25 

     More details

    Language:Abkhazian   Presentation type:Oral presentation (invited, special)  

  119. グリオーマに対する手術戦略 Invited

    本村和也, 齋藤竜太

    CUSA Clarity training seminar in 成田2022  2022.10.1 

     More details

    Language:English   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  120. グリオーマに対する腫瘍摘出について ~周術期てんかん管理も含めて~ Invited

    本村 和也, 齋藤, 竜太

    名古屋脳腫瘍セミナー  2022.2.2 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  121. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也, 齋藤竜太

    Glutamate Conference in Kumamoto  2022.9.14 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  122. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    Brain Tumor Related Epilepsy 周術期エキスパートミーティング in九州  2021.9.22 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  123. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    鶴舞脳腫瘍Webカンファレンス  2021.9.16 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  124. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍治療セミナー  2021.9.30 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  125. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍×てんかん Expert Meeting in 北海道  2021.9.28 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  126. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    脳腫瘍とてんかんExpertMeeting  2021.8.19 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  127. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    てんかん診療セミナー宮城  2021.8.7 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

  128. 脳腫瘍関連てんかんの治療における パラダイムシフトの可能性 ~覚醒下手術からの知見をふまえて~ Invited

    本村和也

    Brain Tumor Related Epilepsy 周術期エキスパートミーティング in東北  2021.9.2 

     More details

    Language:English   Presentation type:Oral presentation (invited, special)  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 2

  1. 感情の神経基盤の解析:島回に対する浸潤脳腫瘍の及ぼす病態の解明

    2017.4

    武田科学振興財団 医学系研究奨励 

      More details

    Grant type:Competitive

  2. 次世代医療機器・ナビゲーション下経頭蓋磁気刺激(nTMS)システムを用いた新たな術前・脳機能マッピング法の確立

    2015.2

    日本脳神経財団 

      More details

    Grant type:Competitive

KAKENHI (Grants-in-Aid for Scientific Research) 8

  1. 覚醒下脳手術における島皮質の自律神経機能に関わる新規神経基盤の解明

    Grant number:21K09174  2021.4 - 2024.3

    科学研究費補助金  

    本村 和也

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

  2. 感情認識における心理・神経基盤解明:脳神経外科学・認知神経科学の融合

    2018.4

    科学研究費補助金  基盤研究(B)

    若林俊彦

      More details

    Authorship:Coinvestigator(s) 

  3. 包括的ゲノムプロファイリングに基づくIDH野生型神経膠腫の新規予後因子の機能解明

    2017.5

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  4. グリオーマの悪性転化に関わる新規バイオマーカーの機能解明

    2013.5 - 2016.3

    科学研究費補助金  若手研究(B)

      More details

    Authorship:Principal investigator 

  5. 幹細胞関連タンパクを発現するトランスポゾンを用いた悪性脳腫瘍発生メカニズムの解明

    2011.5 - 2012.3

    科学研究費補助金  若手研究(B)

      More details

    Authorship:Principal investigator 

    近年我々は、幹細胞関連蛋白の一つであり、Akt の新規基質である Girdin(Nat Cell Biol, 2008)が悪性グリオーマに高発現しており、特に腫瘍形成、分化、浸潤能に関わることを同定した。さらに、Girdin がグリオーマ幹細胞(Glioma-initiating cells; GICs)の分化誘導の suppressor としての役割を持つことを示した。この Girdin を発現する画期的な Sleeping Beauty(SB)トランスポゾンベクター(Nature, 2005)を用いて脳腫瘍自然発生モデルを作成することで、Girdin による腫瘍発生、増殖に関わるメカニズムを解明することがこの研究の主旨である。

  6. オルガノイドモデルを用いた脳腫瘍の悪性転化を誘導する分子メカニズムの解明

    Grant number:23K08497  2023.4 - 2026.3

    科学研究費助成事業  基盤研究(C)

    大岡 史治, 本村 和也

      More details

    Authorship:Coinvestigator(s) 

    近年のビッグデータにより、脳腫瘍には多彩なゲノム・エピゲノム異常が蓄積していることが明らかになった。今後脳腫瘍の新規治療戦略を開発するためには、マスターレギュレーターとして中心的な役割を果たす分子異常を同定することが重要である。本研究では脳腫瘍オルガノイドモデルのゲノム編集を行うことで組織学的な悪性転化が誘導されるモデルを作成する。本モデルを用いて経時的にゲノム・エピゲノム異常を解析することで、悪性転化においてマスターレギュレーターの役割を果たす分子異常を同定する。予後不良な脳腫瘍の未だ明らかになっていない重要な弱点を同定し、新規治療戦略の開発につながる研究になることを期待する。

  7. 感情の神経基盤の解析:島回に対する浸潤脳腫瘍の及ぼす病態の解明

    2017.4

    武田科学振興財団  武田科学振興財団 医学系研究奨励 

      More details

    Grant type:Competitive

  8. 次世代医療機器・ナビゲーション下経頭蓋磁気刺激(nTMS)システムを用いた新たな術前・脳機能マッピング法の確立

    2015.2

    日本脳神経財団  日本脳神経財団 

      More details

    Grant type:Competitive

▼display all

 

Teaching Experience (On-campus) 10

  1. 脳腫瘍、画像誘導覚醒下手術

    2023

  2. 脳腫瘍、画像誘導覚醒下手術

    2022

  3. 脳腫瘍、画像誘導覚醒下手術

    2021

  4. 脳腫瘍、画像誘導覚醒下手術

    2020

  5. 脳腫瘍、画像誘導覚醒下手術

    2019

  6. 脳腫瘍、画像誘導覚醒下手術

    2018

  7. 脳腫瘍、画像誘導覚醒下手術

    2017

  8. 脳腫瘍、画像誘導覚醒下手術

    2016

  9. 脳腫瘍、画像誘導覚醒下手術

    2015

  10. 脳腫瘍、画像誘導覚醒下手術

    2014

▼display all

Teaching Experience (Off-campus) 2

  1. 脳腫瘍、画像誘導覚醒下手術

    2023 Nagoya University)

     More details

    Level:Undergraduate (specialized) 

  2. 脳腫瘍、画像誘導覚醒下手術

    2022 Nagoya University)

     More details

    Level:Undergraduate (specialized) 

 

Media Coverage 5

  1. The Science of Emotion: The Mind's Connection to the Body Internet

    NHK World  Science View  https://www3.nhk.or.jp/nhkworld/en/ondemand/video/2015298/  2023.4

  2. 感情の科学 “体”とつながる心の世界 TV or radio program

    NHK  サイエンスZERO  2022.5

  3. 名大チーム発表、いら立ちなど認識 感情理解助ける「どきどき」

    SankeiBiz  2021.3

  4. 手術前に言語中枢特定 脳腫瘍患者の機能守る

    日経新聞  2020.6

  5. 感情認識する脳部位を特定 心の機能残す手術に応用も Newspaper, magazine

    日経新聞掲載記事  日経新聞  2019.6